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Summary
This report updates the 2008 recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding 
the use of influenza vaccine for the prevention and control of seasonal influenza (CDC. Prevention and control of influenza: 
recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2008;57[No. RR-7]). Information 
on vaccination issues related to the recently identified novel influenza A H1N1 virus will be published later in 2009. The 2009 
seasonal influenza recommendations include new and updated information. Highlights of the 2009 recommendations include 1) 
a recommendation that annual vaccination be administered to all children aged 6 months–18 years for the 2009–10 influenza 
season; 2) a recommendation that vaccines containing the 2009–10 trivalent vaccine virus strains A/Brisbane/59/2007 (H1N1)-
like, A/Brisbane/10/2007 (H3N2)-like, and B/Brisbane/60/2008-like antigens be used; and 3) a notice that recommendations 
for influenza diagnosis and antiviral use will be published before the start of the 2009–10 influenza season. Vaccination efforts 
should begin as soon as vaccine is available and continue through the influenza season. Approximately 83% of the United States 
population is specifically recommended for annual vaccination against seasonal influenza; however, <40% of the U.S. popula-
tion received the 2008–09 influenza vaccine. These recommendations also include a summary of safety data for U.S. licensed 
influenza vaccines. These recommendations and other information are available at CDC’s influenza website (http://www.cdc.gov/
flu); any updates or supplements that might be required during the 2009–10 influenza season also can be found at this website. 
Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC 
influenza website periodically for additional information.
Introduction
In the United States, annual epidemics of seasonal influ-
enza occur typically during the late fall through early spring. 
Influenza viruses can cause disease among persons in any age 
group, but rates of infection are highest among children (1–3). 
Rates of serious illness and death are highest among persons 
aged >65 years, children aged <2 years, and persons of any age 
who have medical conditions that place them at increased risk 
for complications from influenza (1,4,5). An annual average of 
approximately 36,000 deaths during 1990–1999 and 226,000 
hospitalizations during 1979–2001 have been associated with 
influenza epidemics (6,7).
Annual influenza vaccination is the most effective method 
for preventing influenza virus infection and its complications. 
Influenza vaccine can be administered to any person aged >6 
months who does not have contraindications to vaccination 
to reduce the likelihood of becoming ill with influenza or of 
transmitting influenza to others. Trivalent inactivated influenza 
vaccine (TIV) can be used for any person aged >6 months, 
including those with high-risk conditions (Boxes 1 and 2). 
Live, attenuated influenza vaccine (LAIV) may be used for 
healthy, nonpregnant persons aged 2–49 years. No preference 
The material in this report originated in the National Center for 
Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; 
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Immunization Services Division, Lance Rodewald, MD, Director.
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BOX 2. Summary of seasonal influenza vaccination recom-
mendations, 2009: adults
BOX 1. Summary of seasonal influenza vaccination recom-
mendations, 2009: children and adolescents aged 6 months–18 
years
All children aged 6 months–18 years should be vac-
cinated annually.
Children and adolescents at higher risk for influenza 
complications should continue to be a focus of vaccination 
efforts as providers and programs transition to routinely 
vaccinating all children and adolescents, including those 
who:
are aged 6 months–4 years (•	 59 months);
have chronic pulmonary (including asthma), cardiovas-•	
cular (except hypertension), renal, hepatic, cognitive, 
neurologic/neuromuscular, hematological or metabolic 
disorders (including diabetes mellitus);
are immunosuppressed (including immunosuppression •	
caused by medications or by human immunodeficiency 
virus);
are receiving long-term aspirin therapy and therefore •	
might be at risk for experiencing Reye syndrome after 
influenza virus infection;
are residents of long-term care facilities; and•	
will be pregnant during the influenza season.•	
Note: Children aged <6 months cannot receive influenza 
vaccination. Household and other close contacts (e.g., 
daycare providers) of children aged <6 months, including 
older children and adolescents, should be vaccinated.
is indicated for LAIV or TIV when considering vaccination 
of healthy, nonpregnant persons aged 2–49 years. Because 
the safety or effectiveness of LAIV has not been established 
in persons with underlying medical conditions that confer a 
higher risk for influenza complications, these persons should 
be vaccinated only with TIV. Influenza viruses undergo fre-
quent antigenic change (i.e., antigenic drift); to gain immunity 
against viruses in circulation, patients must receive an annual 
vaccination against the influenza viruses that are predicted 
on the basis of viral surveillance data. . Although vaccination 
coverage has increased in recent years for many groups targeted 
for routine vaccination, coverage remains low among most of 
these groups, and strategies to improve vaccination coverage, 
including use of reminder/recall systems and standing orders 
programs, should be implemented or expanded.
Antiviral medications are an adjunct to vaccination and 
are effective when administered as treatment and when used 
for chemoprophylaxis after an exposure to influenza virus. 
However, the emergence since 2005 of resistance to one or 
more of the four licensed antiviral agents (oseltamivir, zana-
mivir, amantadine and rimantadine) among circulating strains 
Annual vaccination against influenza is recommended 
for any adult who wants to reduce the risk of becoming ill 
with influenza or of transmitting it to others. Vaccination 
is recommended for all adults without contraindications 
in the following groups, because these persons either are 
at higher risk for influenza complications, or are close 
contacts of persons at higher risk:
persons aged •	 >50 years;
women who will be pregnant during the influenza •	
season;
persons who have chronic pulmonary (including •	
asthma), cardiovascular (except hypertension), renal, 
hepatic, cognitive, neurologic/neuromuscular, hema-
tological or metabolic disorders (including diabetes 
mellitus);
persons who have immunosuppression (including •	
immunosuppression caused by medications or by 
human immunodeficiency virus;
residents of nursing homes and other long-term care •	
facilities;
health-care personnel;•	
household contacts and caregivers of children aged •	
<5 years and adults aged >50 years, with particular 
emphasis on vaccinating contacts of children aged <6 
months; and
household contacts and caregivers of persons with medi-•	
cal conditions that put them at higher risk for severe 
complications from influenza.
has complicated antiviral treatment and chemoprophylaxis 
recommendations. Updated antiviral treatment and chemo-
prophylaxis recommendations will be provided in a separate 
set of guidelines later in 2009. CDC has issued interim recom-
mendations for antiviral treatment and chemoprophylaxis of 
influenza (8), and these guidelines should be consulted pending 
issuance of new recommendations.
In April 2009, a novel influenza A (H1N1) virus that is 
similar to influenza viruses previously identified in swine was 
determined to be the cause of an influenza respiratory illness 
that spread across North America and was identified in many 
areas of the world by May 2009. The symptoms of novel 
influenza A (H1N1) virus infection are similar to those of 
seasonal influenza, and specific diagnostic testing is required 
to distinguish novel influenza A (H1N1) virus infection from 
seasonal influenza (9). The epidemiology of this illness is still 
being studied and prevention issues related to this newly emerg-
ing influenza virus will be published separately.
Vol. 58 / RR-8 Recommendations and Reports 3
Methods
CDC’s Advisory Committee on Immunization Practices 
(ACIP) provides annual recommendations for the prevention 
and control of influenza. The ACIP Influenza Vaccine Working 
Group* meets monthly throughout the year to discuss newly 
published studies, review current guidelines, and consider 
revisions to the recommendations. As they review the annual 
recommendations for ACIP consideration of the full commit-
tee, members of the working group consider a variety of issues, 
including burden of influenza illness, vaccine effectiveness, 
safety, and coverage in groups recommended for vaccination, 
feasibility, cost-effectiveness, and anticipated vaccine supply. 
Working group members also request periodic updates on 
vaccine and antiviral production, supply, safety and efficacy 
from vaccinologists, epidemiologists, and manufacturers. State 
and local vaccination program representatives are consulted. 
CDC’s Influenza Division (available at http://www.cdc.gov/
flu) provides influenza surveillance and antiviral resistance 
data. The Vaccines and Related Biological Products Advisory 
Committee provides advice on vaccine strain selection to the 
Food and Drug Administration (FDA), which selects the viral 
strains to be used in the annual trivalent influenza vaccines.
Published, peer-reviewed studies are the primary source of 
data used by ACIP in making recommendations for the preven-
tion and control of influenza, but unpublished data that are 
relevant to issues under discussion also might be considered. 
Among studies discussed or cited, those of greatest scientific 
quality and those that measured influenza-specific outcomes 
are the most influential. For example, population-based esti-
mates that use outcomes associated with laboratory-confirmed 
influenza virus infection outcomes contribute the most spe-
cific data for estimates of influenza burden. The best evidence 
for vaccine or antiviral efficacy and effectiveness comes from 
randomized controlled trials that assess laboratory-confirmed 
influenza infections as an outcome measure and consider fac-
tors such as timing and intensity of influenza circulation and 
degree of match between vaccine strains and wild circulating 
strains (10,11). Randomized, placebo-controlled trials cannot 
be performed ethically in populations for which vaccination 
already is recommended, but observational studies that assess 
outcomes associated with laboratory-confirmed influenza 
infection can provide important vaccine or antiviral effective-
ness data. Randomized, placebo-controlled clinical trials are 
the best source of vaccine and antiviral safety data for common 
adverse events; however, such studies do not have the statistical 
power to identify rare but potentially serious adverse events. 
The frequency of rare adverse events that might be associated 
with vaccination is best assessed by reviewing computerized 
medical records from large linked clinical databases and medi-
cal charts of persons who are identified as having a potential 
adverse event after vaccination (12,13). Vaccine coverage data 
from a nationally representative, randomly selected population 
that includes verification of vaccination through health-care 
record review are superior to coverage data derived from 
limited populations or without verification of vaccination; 
however, these data rarely are available for older children or 
adults (14). Finally, studies that assess vaccination program 
practices that improve vaccination coverage are most influential 
in formulating recommendations if the study design includes 
a nonintervention comparison group. In cited studies that 
included statistical comparisons, a difference was considered to 
be statistically significant if the p-value was <0.05 or the 95% 
confidence interval (CI) around an estimate of effect allowed 
rejection of the null hypothesis (i.e., no effect).
These recommendations were presented to the full ACIP 
and approved in February 2009. Modifications were made 
to the ACIP statement during the subsequent review process 
at CDC to update and clarify wording in the document. 
Vaccine recommendations apply only to persons who do not 
have contraindications to vaccine use (see Contraindications 
and Precautions for use of TIV and Contraindications and 
Precautions for use of LAIV). Data presented in this report 
were current as of July 17, 2009. Further updates, if needed, 
will be posted at CDC’s influenza website (http://www.cdc.
gov/flu).
Primary Changes and Updates in 
the Recommendations
The 2009 recommendations include three principal changes 
or updates:
Annual vaccination of all children aged 6 months–18  •
years should begin as soon as the 2009–10 influenza 
vaccine is available. Annual vaccination of all children 
aged 6 months–4 years (59 months) and older children 
with conditions that place them at increased risk for 
complications from influenza should continue to be a 
primary focus of vaccination efforts as providers and 
programs transition to routinely vaccinating all children.
The 2009–10 trivalent vaccine virus strains are A/ •
Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 
(H3N2)-like, and B/Brisbane 60/2008-like antigens.
Most seasonal influenza A (H1N1) virus strains tested  •
from the United States and other countries are now 
resistant to oseltamivir. Recommendations for influ-
enza diagnosis and antiviral use will be published later * A list of members appears on on page 52 of this report.
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in 2009. CDC issued interim recommendations for 
antiviral treatment and chemoprophylaxis of influenza 
in December 2008, and these should be consulted for 
guidance pending recommendations from the ACIP (8). 
Background and Epidemiology
Biology of Influenza
Influenza A and B are the two types of influenza viruses 
that cause epidemic human disease. Influenza A viruses are 
categorized into subtypes on the basis of two surface antigens: 
hemagglutinin and neuraminidase. Since 1977, influenza A 
(H1N1) viruses, influenza A (H3N2) viruses, and influenza 
B viruses have circulated globally. Influenza A (H1N2) viruses 
that probably emerged after genetic reassortment between 
human A (H3N2) and A (H1N1) viruses also have been 
identified in some influenza seasons. In April 2009, human 
infections with a novel influenza A (H1N1) virus were iden-
tified; as of June 2009, infections with the novel influenza 
A (H1N1) virus have been reported worldwide. This novel 
virus is derived partly from influenza A viruses that circulate 
in swine and is antigenically distinct from human influenza A 
(H1N1) viruses in circulation since 1977. Influenza A subtypes 
and B viruses are further separated into groups on the basis of 
antigenic similarities. New influenza virus variants result from 
frequent antigenic change (i.e., antigenic drift) resulting from 
point mutations and recombination events that occur during 
viral replication (15). Recent studies have begun to shed some 
light on the complex molecular evolution and epidemiologic 
dynamics of influenza A viruses (16–18).
Currently circulating influenza B viruses are separated into 
two distinct genetic lineages (Yamagata and Victoria) but are 
not categorized into subtypes. Influenza B viruses undergo 
antigenic drift less rapidly than influenza A viruses. Influenza 
B viruses from both lineages have circulated in most recent 
influenza seasons (19).
Immunity to the surface antigens, particularly the hemag-
glutinin, reduces the likelihood of infection (20). Antibody 
against one influenza virus type or subtype confers limited or no 
protection against another type or subtype of influenza virus. 
Furthermore, antibody to one antigenic type or subtype of 
influenza virus might not protect against infection with a new 
antigenic variant of the same type or subtype (21). Frequent 
emergence of antigenic variants through antigenic drift is the 
virologic basis for seasonal epidemics and is the reason for 
annually reassessing the need to change one or more of the 
recommended strains for influenza vaccines.
More dramatic changes, or antigenic shifts, occur less fre-
quently. Antigenic shift occurs when a new subtype of influenza 
A virus appears and can result in the emergence of a novel 
influenza A virus with the potential to cause a pandemic. New 
influenza A subtypes have the potential to cause a pandemic 
when they are able to cause human illness and demonstrate 
efficient human-to-human transmission and little or no previ-
ously existing immunity has been identified among humans 
(15). Novel influenza A (H1N1) virus is not a new subtype, 
but because the large majority of humans appear to have no 
pre-existing antibody to key novel influenza A (H1N1) virus 
hemagglutinin epitopes, substantial potential exists for wide-
spread infection (16).
Health-Care Use, Hospitalizations, 
and Deaths Attributed to Influenza
In the United States, annual epidemics of influenza typi-
cally occur during the fall or winter months, but the peak of 
influenza activity can occur as late as April or May (Figure 1). 
Influenza-related complications requiring urgent medical care, 
including hospitalizations or deaths, can result from the direct 
effects of influenza virus infection, from complications associ-
ated with age or pregnancy, or from complications of under-
lying cardiopulmonary conditions or other chronic diseases. 
Studies that have measured rates of a clinical outcome without 
a laboratory confirmation of influenza virus infection (e.g., 
respiratory illness requiring hospitalization during influenza 
season) to assess the effect of influenza can be difficult to inter-
pret because of circulation of other respiratory pathogens (e.g., 
respiratory syncytial virus) during the same time as influenza 
viruses (22–24). However, increases in healthcare provider 
visits for acute febrile respiratory illness occur each year dur-
ing the time when influenza viruses circulate. Data from the 
U.S. Outpatient Influenza-like Illness Surveillance Network 
(ILINet) demonstrate the annual increase in physician visits 
for influenza-like illness (ILI)† and for each influenza season; 
for 2009, the data also indicate the recent resurgence of respi-
ratory illness associated with circulation of novel influenza A 
(H1N1) virus (Figure 2) (25,26).
During seasonal influenza epidemics from 1979–1980 
through 2000–2001, the estimated annual overall number 
of influenza-associated hospitalizations in the United States 
ranged from approximately 55,000 to 431,000 per annual 
epidemic (mean: 226,000) (7). The estimated annual number 
of deaths attributed to influenza from the 1990–91 influenza 
season through the 1998–99 season ranged from 17,000 
to 51,000 per epidemic (mean: 36,000) (6). In the United 
States, the estimated number of influenza-associated deaths 
†ILI is defined as fever (temperature of >100°F [>37.8°C) and a cough and/or a 
sore throat in the absence of a known cause other than influenza.
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FIGURE 1. Peak influenza activity, by month — United States, 















Source: Influenza Division, CDC.
FIGURE 2. Percentage of visits for influenza-like illness (ILI)* 
reported by U.S. Outpatient Influenza-like Illness Surveillance 
Network (ILINet),† by surveillance week — United States, 






















* ILI is defined as fever (temperature of >100°F [>37.8°C) and a cough and/or a 
sore throat in the absence of a known cause other than influenza.
† The Outpatient Influenza-like Illness Surveillance Network (ILINet) consists of 
approximately 2,400 health-care providers in 50 states reporting approximately 
16 million patient visits each year. 
§ The 2006–07 and 2007–08 seasons did not have a week 53; therefore the week 
53 data point for those seasons is an average of weeks 52 and 1.
¶ The national baseline is the mean percentage of visits for ILI during nonin-
fluenza weeks for the previous three seasons plus two standard deviations. A 
noninfluenza week is a week during which <10% of specimens tested positive 
for influenza.
increased during 1990–1999. This increase was attributed in 
part to the substantial increase in the number of persons aged 
>65 years who were at increased risk for death from influenza 
complications (6). In one study, an average of approximately 
19,000 influenza-associated pulmonary and circulatory deaths 
per influenza season occurred during 1976–1990 compared 
with an average of approximately 36,000 deaths per season 
during 1990–1999 (6). In addition, influenza A (H3N2) 
viruses, which have been associated with higher mortal-
ity (27), predominated in 90% of influenza seasons during 
1990–1999 compared with compared with 57% of seasons 
during 1976–1990 (6).
Influenza viruses cause disease among persons in all age 
groups (1–5). Rates of infection are highest among children, 
but the risks for complications, hospitalizations, and deaths 
from influenza are higher among persons aged >65 years, 
young children, and persons of any age who have medical 
conditions that place them at increased risk for complications 
from influenza (1,4,5,28–31). Estimated rates of influenza-
associated hospitalizations and deaths varied substantially 
by age group in studies conducted during different influenza 
epidemics. During 1990–1999, estimated average rates of 
influenza-associated pulmonary and circulatory deaths per 
100,000 persons were 0.4–0.6 among persons aged 0–49 
years, 7.5 among persons aged 50–64 years, and 98.3 among 
persons aged >65 years (6).
Children
Among children aged <5 years, influenza-related illness is a 
common cause of visits to medical practices and emergency 
departments (EDs). During two influenza seasons (2002–03 
and 2003–04), the percentage of visits among children aged 
<5 years with acute respiratory illness or fever caused by 
laboratory-confirmed influenza ranged from 10%–19% of 
medical office visits to 6%–29% of EDs visits during the 
influenza season. On the basis of these data, the rate of visits 
to medical clinics for influenza was estimated to be 50–95 per 
1,000 children, and the rate of visits to EDs was estimated to 
be 6–27 per 1,000 children (32). A multiyear study in New 
York City used viral surveillance data to estimate influenza 
strain-specific illness rates among ED visits. In addition to 
the expected variation by season and age group, influenza 
B epidemics were found to be an important cause of illness 
among school-aged children in several seasons, and annual epi-
demics of both influenza A and B peaked among school-aged 
children before other age groups (33). Retrospective studies 
using medical records data have demonstrated similar rates of 
illness among children aged <5 years during other influenza 
seasons (29,34,35). During the influenza season, an estimated 
7–12 additional outpatient visits and 5–7 additional antibiotic 
prescriptions per 100 children aged <15 years have been docu-
mented when compared with periods when influenza viruses 
are not circulating, with rates decreasing with increasing age 
of the child (35). During 1993–2004 in the Boston area, the 
rate of ED visits for respiratory illness that was attributed to 
influenza virus based on viral surveillance data among children 
aged <7 years during the winter respiratory illness season ranged 
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from 22.0 per 1,000 children aged 6–23 months to 5.4 per 
1,000 children aged 5–7 years (36).
Rates of influenza-associated hospitalization are substantially 
higher among infants and young children than among older 
children when influenza viruses are in circulation and are 
similar to rates for other groups considered at high risk for 
influenza-related complications (37–42), including persons 
aged >65 years (35,39). During 1979–2001, on the basis of 
data from a national sample of hospital discharges of influenza-
associated hospitalizations among children aged <5 years, the 
estimated rate of influenza-associated hospitalizations in the 
United States was 108 hospitalizations per 100,000 person-
years (7). Recent population-based studies that measured hos-
pitalization rates for laboratory-confirmed influenza in young 
children have documented hospitalization rates that are similar 
to or higher than rates derived from studies that analyzed hos-
pital discharge data (32,34,41,43,44). Annual hospitalization 
rates for laboratory-confirmed influenza decrease with increas-
ing age, ranging from 240–720 per 100,000 children aged <6 
months to approximately 20 per 100,000 children aged 2–5 
years (32). Hospitalization rates for children aged <5 years with 
high-risk medical conditions are approximately 250–500 per 
100,000 children (29,31,45).
Influenza-associated deaths are uncommon among children. 
An estimated annual average of 92 influenza-related deaths (0.4 
deaths per 100,000 persons) occurred among children aged <5 
years during the 1990s compared with 32,651 deaths (98.3 
per 100,000 persons) among adults aged >65 years (6). Of 
153 laboratory-confirmed influenza-related pediatric deaths 
reported during the 2003–04 influenza season, 96 (63%) 
deaths occurred among children aged <5 years and 61 (40%) 
among children aged <2 years. Among the 149 children who 
died and for whom information on underlying health status 
was available, 100 (67%) did not have an underlying medi-
cal condition that was an indication for vaccination at that 
time (46). In California during the 2003–04 and 2004–05 
influenza seasons, 51% of children with laboratory-confirmed 
influenza who died and 40% of those who required admission 
to an intensive care unit had no underlying medical condi-
tions (47). These data indicate that although children with 
risk factors for influenza complications are at higher risk for 
death, the majority of pediatric deaths occur among children 
with no known high-risk conditions. The annual number of 
influenza-associated deaths among children reported to CDC 
for the past four influenza seasons has ranged from 44 during 
2004–05 to 84 during 2007–08 (48). As of July 8, 2009, a 
total of 17 deaths caused by novel influenza A (H1N1) virus 
infection have occurred in 2009 among children in the United 
States (CDC, unpublished data, 2009).
Death associated with laboratory-confirmed influenza virus 
infection among children (defined as persons aged <18 years) 
is a nationally reportable condition. Deaths among children 
that have been attributed to co-infection with influenza and 
Staphylococcus aureus, particularly methicillin-resistant S. aureus 
(MRSA), have increased during the preceding four influenza 
seasons (26,49). The reason for this increase is not established 
but might reflect an increasing prevalence within the general 
population of colonization with MRSA strains, some of which 
carry certain virulence factors (50,51).
Adults
Hospitalization rates during the influenza season are sub-
stantially increased for persons aged >65 years. One retrospec-
tive analysis based on data from managed-care organizations 
collected during 1996–2000 estimated that the risk during 
influenza season among persons aged >65 years with under-
lying conditions that put them at risk for influenza-related 
complications (i.e., one or more of the conditions listed as 
indications for vaccination) was approximately 560 influenza-
associated hospitalizations per 100,000 persons compared 
with approximately 190 per 100,000 healthy persons. Persons 
aged 50–64 years with underlying medical conditions also 
were at substantially increased risk for hospitalizations during 
influenza season compared with healthy adults aged 50–64 
years. No increased risk for influenza-related hospitalizations 
was demonstrated among healthy adults aged 50–64 years 
or among those aged 19–49 years, regardless of underlying 
medical conditions (28).
Influenza is an important contributor to the annual 
increase in deaths attributed to pneumonia and influenza 
that is observed during the winter months (Figure 3). During 
1976–2001, an estimated yearly average of 32,651 (90%) 
influenza-related deaths occurred among adults aged >65 
years (6). Risk for influenza-related death was highest among 
the oldest elderly, with persons aged >85 years 16 times more 
likely to die from an influenza-related illness than persons aged 
65–69 years (6).
The duration of influenza symptoms is prolonged and the 
severity of influenza illness increased among persons with 
human immunodeficiency virus (HIV) infection (52–56). A 
retrospective study of young and middle-aged women enrolled 
in Tennessee’s Medicaid program determined that the attribut-
able risk for cardiopulmonary hospitalizations among women 
with HIV infection was higher during influenza seasons than 
it was either before or after influenza was circulating. The risk 
for hospitalization was higher for HIV-infected women than 
it was for women with other underlying medical conditions 
(57). Another study estimated that the risk for influenza-
Vol. 58 / RR-8 Recommendations and Reports 7
FIGURE 3. Percentage of all deaths attributed to pneumonia 























* Each week, the vital statistics offices of 122 cities report the total number of 
death certificates received and the number of those for which pneumonia or 
influenza (P&I) was listed as the underlying or contributing cause of death by 
age group. The percentage of all deaths attributable to P&I are compared with 
a seasonal baseline and epidemic threshold value calculated for each week.
† An increase of 1.645 standard deviations above the seasonal baseline deaths is 
considered the “epidemic threshold,” i.e., the point at which the observed pro-
portion of deaths attributed to pneumonia or influenza was significantly higher 
than would be expected at that time of the year in the absence of substantial 
influenza-related mortality.
§ The seasonal baseline of P&I deaths is calculated using a periodic regression 
model that incorporates a robust regression procedure applied to data from the 
previous 5 years.
related death was 94–146 deaths per 100,000 persons with 
acquired immunodeficiency syndrome (AIDS) compared 
with 0.9–1.0 deaths per 100,000 persons aged 25–54 years 
and 64–70 deaths per 100,000 persons aged >65 years in the 
general population (58).
Influenza-related excess deaths among pregnant women were 
reported during the pandemics of 1918–1919 and 1957–1958 
(59–63). Case reports and several epidemiologic studies also 
indicate that pregnancy increases the risk for influenza com-
plications (64–69) for the mother. The majority of studies that 
have attempted to assess the effect of influenza on pregnant 
women have measured changes in excess hospitalizations for 
respiratory illness during influenza season but not laboratory-
confirmed influenza hospitalizations. Pregnant women have an 
increased number of medical visits for respiratory illnesses dur-
ing influenza season compared with nonpregnant women (70). 
Hospitalized pregnant women with respiratory illness during 
influenza season have increased lengths of stay compared with 
hospitalized pregnant women without respiratory illness. Rates 
of hospitalization for respiratory illness were twice as common 
during influenza season (71). A retrospective cohort study of 
approximately 134,000 pregnant women conducted in Nova 
Scotia during 1990–2002 compared medical record data for 
pregnant women to data from the same women during the 
year before pregnancy. Among pregnant women, 0.4% were 
hospitalized and 25% visited a clinician during pregnancy for 
a respiratory illness. The rate of third-trimester hospital admis-
sions during the influenza season was five times higher than the 
rate during the influenza season in the year before pregnancy 
and more than twice as high as the rate during the noninfluenza 
season. An excess of 1,210 hospital admissions in the third 
trimester per 100,000 pregnant women with comorbidities 
and 68 admissions per 100,000 women without comorbidi-
ties was reported (72). In one study, pregnant women with 
respiratory hospitalizations did not have an increase in adverse 
perinatal outcomes or delivery complications (73); another 
study indicated an increase in delivery complications, including 
fetal distress, preterm labor, and cesarean delivery. However, 
infants born to women with laboratory-confirmed influenza 
during pregnancy do not have higher rates of low birth weight, 
congenital abnormalities, or lower Apgar scores compared with 
infants born to uninfected women (64,74).
options for Controlling Influenza
The most effective strategy for preventing influenza is annual 
vaccination (10,15). Strategies that focus on providing routine 
vaccination to persons at higher risk for influenza complica-
tions have long been recommended, although coverage among 
the majority of these groups remains low. Routine vaccina-
tion of certain persons (e.g., children, contacts of persons at 
risk for influenza complications, and health-care personnel 
[HCP]) who serve as a source of influenza virus transmis-
sion might provide additional protection to persons at risk 
for influenza complications and reduce the overall influenza 
burden. However, coverage levels among these persons need 
to be increased before effects on transmission can be mea-
sured reliably. Antiviral drugs used for chemoprophylaxis or 
treatment of influenza are adjuncts to vaccine but are not 
substitutes for annual vaccination. However, antiviral drugs 
might be underused among those hospitalized with influenza 
(75). Nonpharmacologic interventions (e.g., advising frequent 
handwashing and improved respiratory hygiene) are reasonable 
and inexpensive; these strategies have been demonstrated to 
reduce respiratory diseases; reductions in detectable influenza 
A viruses on hands after handwashing also have been demon-
strated (76–78). Few data are available to assess the effects of 
community-level respiratory disease mitigation strategies (e.g., 
closing schools, avoiding mass gatherings, or using respiratory 
protection) on reducing influenza virus transmission during 
typical seasonal influenza epidemics (79,80).
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Influenza Vaccine Efficacy, 
Effectiveness, and Safety
Evaluating Influenza Vaccine Efficacy 
and Effectiveness Studies
The efficacy (i.e., prevention of illness among vaccinated 
persons in controlled trials) and effectiveness (i.e., prevention 
of illness in vaccinated populations) of influenza vaccines 
depend in part on the age and immunocompetence of the 
vaccine recipient, the degree of similarity between the viruses 
in the vaccine and those in circulation (see Effectiveness of 
Influenza Vaccination when Circulating Influenza Virus Strains 
Differ from Vaccine Strains), and the outcome being measured. 
Influenza vaccine efficacy and effectiveness studies have used 
multiple possible outcome measures, including the prevention 
of medically attended acute respiratory illness (MAARI), pre-
vention of laboratory-confirmed influenza virus illness, preven-
tion of influenza or pneumonia-associated hospitalizations or 
deaths, or prevention of seroconversion to circulating influenza 
virus strains. Efficacy or effectiveness for more specific out-
comes such as laboratory-confirmed influenza typically will be 
higher than for less specific outcomes such as MAARI because 
the causes of MAARI include infections with other pathogens 
that influenza vaccination would not be expected to prevent 
(81). Observational studies that compare less-specific outcomes 
among vaccinated populations to those among unvaccinated 
populations are subject to biases that are difficult to control 
for during analyses. For example, an observational study that 
determines that influenza vaccination reduces overall mortal-
ity might be biased if healthier persons in the study are more 
likely to be vaccinated (82,83). Randomized controlled trials 
that measure laboratory-confirmed influenza virus infections 
as the outcome are the most persuasive evidence of vaccine 
efficacy, but such trials cannot be conducted ethically among 
groups recommended to receive vaccine annually.
Influenza Vaccine Composition
Both LAIV and TIV contain strains of influenza viruses that 
are antigenically equivalent to the annually recommended 
strains: one influenza A (H3N2) virus, one influenza A (H1N1) 
virus, and one influenza B virus. Each year, one or more virus 
strains in the vaccine might be changed on the basis of global 
surveillance for influenza viruses and the emergence and spread 
of new strains. For the 2009–10 influenza season, the influenza 
B vaccine virus strain was changed to B/Brisbane/60/2008, a 
representative of the B/Victoria lineage) compared with the 
2008–09 season. The influenza A (H1N1 and H3N2 vaccine 
virus strains were not changed (84). Viruses for both types of 
currently licensed vaccines are grown in eggs. Both vaccines are 
administered annually to provide optimal protection against 
influenza virus infection (Table 1). Both TIV and LAIV are 
widely available in the United States. Although both types 
of vaccines are expected to be effective, the vaccines differ in 
several respects (Table 1).
Major Differences Between 
tIV and LAIV
During the preparation of TIV, the vaccine viruses are made 
noninfectious (i.e., inactivated or killed) (15). Only subvirion 
and purified surface antigen preparations of TIV (often referred 
to as “split” and subunit vaccines, respectively) are available in 
the United States. TIV contains killed viruses and thus can-
not cause influenza. LAIV contains live, attenuated influenza 
viruses that have the potential to cause mild signs or symptoms 
(e.g., runny nose, nasal congestion, fever, or sore throat). 
LAIV is administered intranasally by sprayer, whereas TIV is 
administered intramuscularly by injection. LAIV is licensed 
for use among nonpregnant persons aged 2–49 years; safety 
has not been established in persons with underlying medical 
conditions that confer a higher risk for influenza complica-
tions. TIV is licensed for use among persons aged >6 months, 
including those who are healthy and those with chronic medical 
conditions (Table 1).
Correlates of Protection after 
Vaccination
Immune correlates of protection against influenza infection 
after vaccination include serum hemagglutination inhibition 
antibody and neutralizing antibody (20,85). Increased levels 
of antibody induced by vaccination decrease the risk for illness 
caused by strains that are antigenically similar to those strains 
of the same type or subtype included in the vaccine (86–89). 
The majority of healthy children and adults have high titers 
of antibody after vaccination (87,90). Although immune 
correlates such as achievement of certain antibody titers after 
vaccination correlate well with immunity on a population level, 
the significance of reaching or failing to reach a certain antibody 
threshold is not well understood on the individual level. Other 
immunologic correlates of protection that might best indicate 
clinical protection after receipt of an intranasal vaccine such as 
LAIV (e.g., mucosal antibody) are more difficult to measure 
(91,92). Laboratory measurements that correlate with protec-
tive immunity induced by LAIV have been described, including 
measurement of cell-mediated immunity with ELISPOT assays 
that measure gamma-interferon (89).
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TABLE 1. Live, attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (TIV) for seasonal influenza, 
United States formulations
Factor LAIV TIV
Route of administration Intranasal spray Intramuscular injection
Type of vaccine Live virus Noninfectious virus (i.e., 
inactivated)
No. of included virus strains Three (two influenza A, one 
influenza B) 
Three (two influenza A, one 
influenza B)
Vaccine virus strains updated Annually Annually
Frequency of administration Annually* Annually*
Approved age Persons aged 2–49 yrs† Persons aged >6 mos
Interval between 2 doses recommended for children aged >6 mos – 8 yrs who are 
receiving influenza vaccine for the first time
4 wks 4 wks
Can be administered to persons with medical risk factors for influenza-related 
complications†
No Yes
Can be administered to children with asthma or children aged 2–4 yrs with 
wheezing in the past year§
No Yes
Can be administered to family members or close contacts of immunosuppressed 
persons not requiring a protected environment
Yes Yes
 
Can be administered to family members or close contacts of immunosuppressed 
persons requiring a protected environment  (e.g., hematopoietic stem cell transplant 
recipient)
No Yes
Can be administered to family members or close contacts of persons at high risk 
but not severely immunosuppressed
Yes Yes
 
Can be simultaneously administered with other vaccines Yes¶ Yes**
If not simultaneously administered, can be administered within 4 wks of 
another live vaccine
Space 4 wks apart Yes
 
If not simultaneously administered, can be administered within 4 wks of 
an inactivated vaccine
Yes Yes
 * Children aged 6 months–8 years who have never received influenza vaccine before should receive 2 doses. Those who only receive 1 dose in their first 
year of vaccination should receive 2 doses in the following year, spaced 4 weeks apart. 
 † Persons at higher risk for complications of influenza infection because of underlying medical conditions should not receive LAIV. Persons at higher risk 
for complications of influenza infection because of underlying medical conditions include adults and children with chronic disorders of the pulmonary 
or cardiovascular systems; adults and children with chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, 
or immunnosuppression; children and adolescents receiving long-term aspirin therapy (at risk for developing Reye syndrome after wild-type influenza 
infection); persons who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can 
compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration; pregnant women; and residents of 
nursing homes and other chronic-care facilities that house persons with chronic medical conditions.  
 § Clinicians and immunization programs should screen for possible reactive airways diseases when considering use of LAIV for children aged 2–4 years 
and should avoid use of this vaccine in children with asthma or a recent wheezing episode. Health-care providers should consult the medical record, when 
available, to identify children aged 2–4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be 
at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2–4 years should be 
asked: “In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?” Children whose parents or caregivers 
answer “yes” to this question and children who have asthma or who had a wheezing episode noted in the medical record during the preceding 12 months 
should not receive LAIV. 
 ¶ LAIV coadministration has been evaluated systematically only among children aged 12–15 months who received measles, mumps, and rubella vaccine 
or varicella vaccine.
 ** TIV coadministration has been evaluated systematically only among adults who received pneumococcal polysaccharide or zoster vaccine. 
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Immunogenicity, Efficacy, and 
Effectiveness of tIV
Children
Children aged >6 months typically have protective levels of 
anti-influenza antibody against specific influenza virus strains 
after receiving the recommended number of doses of influenza 
vaccine (85 90 93–97). In most seasons, one or more vaccine 
antigens are changed compared with the previous season. In 
consecutive years when vaccine antigens change, children aged 
<9 years who received only 1 dose of vaccine in their first year of 
vaccination are less likely to have protective antibody responses 
when administered only a single dose during their second year 
of vaccination compared with children who received 2 doses 
in their first year of vaccination (98–100).
When the vaccine antigens do not change from one season to 
the next, priming children aged 6–23 months with a single dose 
of vaccine in the spring followed by a dose in the fall engen-
ders similar antibody responses compared with a regimen of 
2 doses in the fall (101). However, one study conducted during 
a season when the vaccine antigens did not change compared 
with the previous season estimated 62% effectiveness against 
ILI for healthy children who had received only 1 dose in the 
previous influenza season and only 1 dose in the study season 
compared with 82% for those who received 2 doses separated 
by >4 weeks during the study season (102).
The antibody response among children at higher risk for 
influenza-related complications (e.g., children with chronic 
medical conditions) might be lower than those reported typi-
cally among healthy children (103,104). However, antibody 
responses among children with asthma are similar to those 
of healthy children and are not substantially altered during 
asthma exacerbations requiring short-term prednisone treat-
ment (105).
Vaccine effectiveness studies also have indicated that 2 doses 
are needed to provide adequate protection during the first sea-
son that young children are vaccinated. Among children aged 
<5 years who have never received influenza vaccine previously 
or who received only 1 dose of influenza vaccine in their first 
year of vaccination, vaccine effectiveness is lower compared 
with children who received 2 doses in their first year of being 
vaccinated. Two large retrospective studies of young children 
who had received only 1 dose of TIV in their first year of 
being vaccinated determined that no decrease was observed in 
ILI-related office visits compared with unvaccinated children 
(102,106). Similar results were reported in a case-control study 
of children aged 6–59 months (107). These results, along with 
the immunogenicity data indicating that antibody responses 
are significantly higher when young children are given 2 doses, 
are the basis for the recommendation that all children aged <9 
years who are being vaccinated for the first time should receive 
2 vaccine doses separated by at least 4 weeks.
Estimates of vaccine efficacy or effectiveness among children 
aged >6 months have varied by season and study design. In 
a randomized trial conducted during five influenza seasons 
(1985–1990) in the United States among children aged 1–15 
years, annual vaccination reduced laboratory-confirmed 
influenza A substantially (77%–91%) (87). A limited 1-year 
placebo-controlled study reported vaccine efficacy against 
laboratory-confirmed influenza illness of 56% among healthy 
children aged 3–9 years and 100% among healthy children 
and adolescents aged 10–18 years (108). A randomized, 
double-blind, placebo-controlled trial conducted during two 
influenza seasons among children aged 6–24 months indicated 
that efficacy was 66% against culture-confirmed influenza ill-
ness during the 1999–00 influenza season but did not reduce 
culture-confirmed influenza illness significantly during the 
2000–20 influenza season (109).
A case-control study conducted during the 2003–04 season 
found vaccine effectiveness of 49% against laboratory-con-
firmed influenza (107). An observational study among children 
aged 6–59 months with laboratory-confirmed influenza com-
pared with children who tested negative for influenza reported 
vaccine effectiveness of 44% in the 2003–04 influenza season 
and 57% during the 2004–05 season (110). Partial vaccination 
(only 1 dose for children being vaccinated for the first time) 
was not effective in either study. During an influenza season 
(2003–04) with a suboptimal vaccine match, a retrospective 
cohort study conducted among approximately 30,000 children 
aged 6 months–8 years indicated vaccine effectiveness of 51% 
against medically attended, clinically diagnosed pneumonia or 
influenza (i.e., no laboratory confirmation of influenza) among 
fully vaccinated children and 49% among approximately 
5,000 children aged 6–23 months (106). Another retrospec-
tive cohort study of similar size conducted during the same 
influenza season in Denver but limited to healthy children 
aged 6–21 months estimated clinical effectiveness of 2 TIV 
doses to be 87% against pneumonia or influenza-related office 
visits (102). Among children, TIV effectiveness might increase 
with age (87,111). A systematic review of published studies 
estimated vaccine effectiveness at 59% for children aged >2 
years but concluded that additional evidence was needed to 
demonstrate effectiveness among children aged 6 months–2 
years (112).
Because of the recognized influenza-related disease burden 
among children with other chronic diseases or immunosup-
pression and the long-standing recommendation for vaccina-
tion of these children, randomized placebo-controlled studies 
to study efficacy in these children have not been conducted. 
In a nonrandomized controlled trial among children aged 2–6 
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years and 7–14 years who had asthma, vaccine efficacy was 
54% and 78% against laboratory-confirmed influenza type 
A infection and 22% and 60% against laboratory-confirmed 
influenza type B infection, respectively. Vaccinated children 
aged 2–6 years with asthma did not have substantially fewer 
type B influenza virus infections compared with the control 
group in this study (113). The association between vaccina-
tion and prevention of asthma exacerbations is unclear. One 
study suggested that vaccination might provide protection 
against asthma exacerbations (114); however, other studies 
of children with asthma have not demonstrated decreased 
exacerbations (115).
TIV has been demonstrated to reduce acute otitis media in 
some studies. Two studies have reported that TIV decreases the 
risk for influenza-related otitis media by approximately 30% 
among children with mean ages of 20 and 27 months, respec-
tively (116,117). However, a large study conducted among 
children with a mean age of 14 months indicated that TIV 
was not effective against acute otitis media (109). Influenza 
vaccine effectiveness against a nonspecific clinical outcome such 
as acute otitis media, which is caused by a variety of pathogens 
and is not typically diagnosed using influenza virus culture, 
would be expected to be relatively low.
Adults Aged <65 Years
One dose of TIV is highly immunogenic in healthy adults 
aged <65 years. Limited or no increase in antibody response 
is reported among adults when a second dose is administered 
during the same season (118–120). When the vaccine and 
circulating viruses are antigenically similar, TIV prevents 
laboratory-confirmed influenza illness among approximately 
70%–90% of healthy adults aged <65 years in randomized 
controlled trials (121–124). Vaccination of healthy adults also 
has resulted in decreased work absenteeism and decreased use 
of health-care resources, including use of antibiotics, when the 
vaccine and circulating viruses are well-matched (121–123). 
Efficacy or effectiveness against laboratory-confirmed influenza 
illness was 47%–77% in studies conducted during different 
influenza seasons when the vaccine strains were antigenically 
dissimilar to the majority of circulating strains (117,119,121–
124). However, effectiveness among healthy adults against 
influenza-related hospitalization, measured in the most recent 
of these studies, was 90% (125).
In certain studies, persons with certain chronic diseases have 
lower serum antibody responses after vaccination compared 
with healthy young adults and can remain susceptible to influ-
enza virus infection and influenza-related upper respiratory 
tract illness (126,127). Vaccine effectiveness among adults aged 
<65 years who are at higher risk for influenza complications 
typically is lower than that reported for healthy adults. In a 
case-control study conducted during the 2003–04 influenza 
season, when the vaccine was a suboptimal antigenic match 
to many circulating virus strains, effectiveness for prevention 
of laboratory-confirmed influenza illness among adults aged 
50–64 years with high-risk conditions was 48% compared with 
60% for healthy adults (125). Effectiveness against hospitaliza-
tion among adults aged 50–64 years with high-risk conditions 
was 36% compared with 90% effectiveness among healthy 
adults in that age range (125). A randomized controlled trial 
among adults in Thailand with chronic obstructive pulmonary 
disease (median age: 68 years) indicated a vaccine effectiveness 
of 76% in preventing laboratory-confirmed influenza during 
a season when viruses were well-matched to vaccine viruses. 
Effectiveness did not decrease with increasing severity of 
underlying lung disease (128).
Few randomized controlled trials have studied the effect 
of influenza vaccination on noninfluenza outcomes. A ran-
domized controlled trial conducted in Argentina among 301 
adults hospitalized with myocardial infarction or undergoing 
angioplasty for cardiovascular disease (56% of whom were aged 
>65 years) found that a significantly lower percentage (6%) of 
cardiovascular deaths occurred among vaccinated persons at 
1 year after vaccination compared with unvaccinated persons 
(17%) (129). A randomized, double-blind, placebo-controlled 
study conducted in Poland among 658 persons with coronary 
artery disease indicated that significantly fewer vaccinated 
persons vaccinated persons had a cardiac ischemic event dur-
ing the 9 months of follow up compared with unvaccinated 
persons (p <0.05) (130).
Observational studies that have measured clinical endpoints 
without laboratory confirmation of influenza virus infection, 
typically have demonstrated substantial reductions in hospital-
izations or deaths among adults with risk factors for influenza 
complications. In a case-control study conducted during 
1999–2000 in Denmark among adults aged <65 years with 
underlying medical conditions, vaccination reduced deaths 
attributable to any cause 78% and reduced hospitalizations 
attributable to respiratory infections or cardiopulmonary dis-
eases 87% (131). A benefit was reported after the first vaccina-
tion and increased with subsequent vaccinations in subsequent 
years (132). Among patients with diabetes mellitus, vaccination 
was associated with a 56% reduction in any complication, a 
54% reduction in hospitalizations, and a 58% reduction in 
deaths (133). Certain experts have noted that the substantial 
effects on morbidity and mortality among those who received 
influenza vaccination in these observational studies should be 
interpreted with caution because of the difficulties in ensur-
ing that those who received vaccination had similar baseline 
health status as those who did not (82,83). One meta-analysis 
of published studies concluded that evidence was insufficient to 
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demonstrate that persons with asthma benefit from vaccination 
(134). However, a meta-analysis that examined effectiveness 
among persons with chronic obstructive pulmonary disease 
identified evidence of benefit from vaccination (135).
Immunocompromised Persons
TIV produces adequate antibody concentrations against 
influenza among vaccinated HIV-infected persons who have 
minimal AIDS-related symptoms and normal or near-normal 
CD4+ T-lymphocyte cell counts (136–138). Among persons 
who have advanced HIV disease and low CD4+ T-lymphocyte 
cell counts, TIV might not induce protective antibody titers 
(138,139); a second dose of vaccine does not improve the 
immune response in these persons (139,140). A random-
ized, placebo-controlled trial determined that TIV was highly 
effective in preventing symptomatic, laboratory-confirmed 
influenza virus infection among HIV-infected persons with 
a mean of 400 CD4+ T-lymphocyte cells/mm3; however, a 
limited number of persons with CD4+ T-lymphocyte cell 
counts of <200 were included in that study (140). A non-
randomized study of HIV-infected persons determined that 
influenza vaccination was most effective among persons with 
>100 CD4+ cells and among those with <30,000 viral copies 
of HIV type-1/mL (53).
On the basis of certain limited studies, immunogenicity 
for persons with solid organ transplants varies according to 
transplant type. Among persons with kidney or heart trans-
plants, the proportion who developed seroprotective antibody 
concentrations was similar or slightly reduced compared with 
healthy persons (141–143). However, a study among per-
sons with liver transplants indicated reduced immunologic 
responses to influenza vaccination (144–146), especially if 
vaccination occurred within the 4 months after the transplant 
procedure (144).
Pregnant Women and neonates
Pregnant women have protective levels of anti-influenza 
antibodies after vaccination (147,148). Passive transfer of 
anti-influenza antibodies that might provide protection from 
vaccinated women to neonates has been reported (147,149–
151). A retrospective, clinic-based study conducted during 
1998–2003 documented a nonsignificant trend toward fewer 
episodes of MAARI during one influenza season among vacci-
nated pregnant women compared with unvaccinated pregnant 
women and substantially fewer episodes of MAARI during the 
peak influenza season (148). However, a retrospective study 
conducted during 1997–2002 that used clinical records data 
did not indicate a reduction in ILI among vaccinated pregnant 
women or their infants (152). In another study conducted 
during 1995–2001, medical visits for respiratory illness among 
the infants were not substantially reduced (153). One random-
ized controlled trial conducted in Bangladesh that provided 
vaccination to pregnant women during the third trimester 
demonstrated a 29% reduction in respiratory illness with fever 
and a 36% reduction in respiratory illness with fever among 
their infants during the first 6 months after birth. In addi-
tion, infants born to vaccinated women had a 63% reduction 
in laboratory-confirmed influenza illness during the first 6 
months of life (154). All women in this trial breastfed their 
infants (mean duration: 14 weeks).
older Adults
Adults aged >65 years typically have a diminished immune 
response to influenza vaccination compared with young healthy 
adults, suggesting that immunity might be of shorter dura-
tion (although still extending through one influenza season) 
(155,156). However, a review of the published literature con-
cluded that no clear evidence existed that immunity declined 
more rapidly in the elderly (157), and additional vaccine 
doses during the same season do not increase the antibody 
response (118,120). Infections among the vaccinated elderly 
might be associated with an age-related reduction in ability 
to respond to vaccination rather than reduced duration of 
immunity (127,128). One prospective cohort study found 
that immunogenicity among hospitalized persons who were 
either aged >65 years or who were aged 18–64 years and had 
one or more chronic medical conditions was similar compared 
with outpatients (158).
The only randomized controlled trial among community-
dwelling persons aged >60 years reported a vaccine efficacy of 
58% (CI = 26%–77%) against laboratory-confirmed influenza 
illness during a season when the vaccine strains were considered 
to be well-matched to circulating strains (159). Additional 
information from this trial published separately indicated that 
efficacy among those aged >70 years was 57% (CI = -36%–
87%), similar to younger persons. However, few persons aged 
>75 years participated in this study, and the wide confidence 
interval for the estimate of efficacy among participants aged 
>70 years included 0 (160). Influenza vaccine effectiveness 
in preventing MAARI among the elderly in nursing homes 
has been estimated at 20%–40% (161,162), and reported 
outbreaks among well-vaccinated nursing home populations 
have suggested that vaccination might not have any significant 
effectiveness when circulating strains are drifted from vaccine 
strains (163,164). In contrast, some studies have indicated that 
vaccination can be up to 80% effective in preventing influenza-
related death (161,165–167). Among elderly persons not living 
in nursing homes or similar long-term–care facilities, influenza 
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vaccine is 27%–70% effective in preventing hospitalization for 
pneumonia and influenza (168–170). Influenza vaccination 
reduces the frequency of secondary complications and reduces 
the risk for influenza-related hospitalization and death among 
community-dwelling adults aged >65 years with and without 
high-risk medical conditions (e.g., heart disease and diabetes) 
(169–174). However, studies demonstrating large reductions 
in hospitalizations and deaths among the vaccinated elderly 
have been conducted using medical record databases and have 
not measured reductions in laboratory-confirmed influenza 
illness. These studies have been challenged because of concerns 
that they have not adequately controlled for differences in the 
propensity for healthier persons to be more likely than less 
healthy persons to receive vaccination (82,83,166,175–177).
tIV Dosage, Administration, and 
Storage
The composition of TIV varies according to manufacturer, 
and package inserts should be consulted. TIV formulations 
in multidose vials contain the vaccine preservative thimerosal; 
preservative-free, single-dose preparations also are available. 
TIV should be stored at 35°F–46°F (2°C–8°C) and should 
not be frozen. TIV that has been frozen should be discarded. 
Dosage recommendations and schedules vary according to 
age group (Table 2). Vaccine prepared for a previous influenza 
season should not be administered to provide protection for 
any subsequent season.
The intramuscular route is recommended for TIV. Adults 
and older children should be vaccinated in the deltoid muscle. 
A needle length of >1 inch (>25 mm) should be considered for 
persons in these age groups because needles of <1 inch might be 
of insufficient length to penetrate muscle tissue in certain adults 
and older children (178). When injecting into the deltoid 
muscle among children with adequate deltoid muscle mass, a 
needle length of 7/8–1.25 inches is recommended (179).
Infants and young children should be vaccinated in the 
anterolateral aspect of the thigh. A needle length of 7/8–1 inch 
should be used for children aged <12 months.




Mercury content  
(mcg Hg/0.5 mL dose) Age group
No. of 
doses Route
TIV* Fluzone Sanofi Pasteur 0.25mL prefilled syringe
0.5 mL prefilled syringe
0.5 mL vial


















TIV Fluvirin Novartis Vaccine 5.0 mL multidose vial 24.5 >4 yrs 1 or 2 Intramuscular
TIV Fluarix GlaxoSmithKline 0.5 mL prefilled syringe <1.0 >18 yrs 1 Intramuscular
TIV FluLaval GlaxoSmithKline 5.0 mL multidose vial 25 >18 yrs 1 Intramuscular
TIV Afluria CSL Biotherapies 0.5 mL prefilled syringe 
5.0 mL multidose vial
0
25
>18 yrs 1 Intramuscular
LAIV
¶
FluMist** MedImmune 0.2 mL sprayer 0 2–49 yrs 1 or 2†† Intranasal
 * Trivalent inactivated vaccine. A 0.5-mL dose contains 15 mcg each of A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and  B/
Brisbane/60/2008-like antigens.
 † Two doses administered at least 1 month apart are recommended for children aged 6 months–8 years who are receiving TIV for the first time and those 
who only received 1 dose in their first year of vaccination should receive 2 doses in the following year. 
 § For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the 
anterolateral aspect of the thigh.
 ¶ Live attenuated influenza vaccine. A 0.2-mL dose contains 106.5–7.5 fluorescent focal units of live attenuated influenza virus reassortants of each of the 
three strains for the 2008–09 influenza season: A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), and B/Brisbane/60/2008.
 ** FluMist is shipped refrigerated and stored in the refrigerator at 2°C–8°C (36°F to 46°F) after arrival in the immunization clinic. The dose is 0.2 mL divided 
equally between each nostril. FluMist should not be administered to persons with asthma. Health-care providers should consult the medical record, 
when available, to identify children aged 2–4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who 
might be at greater risk for asthma and possibly at increased risk for wheezing after receiving FluMist, parents or caregivers of children aged 2–4 years 
should be asked: “In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?” Children whose parents 
or caregivers answer “yes” to this question and children who have asthma or who had a wheezing episode noted in the medical record during the 
preceding 12 months should not receive FluMist.
 †† Two doses administered at least 4 weeks apart are recommended for children aged 2–8 years who are receiving LAIV for the first time, and those who 
only received 1 dose in their first year of vaccination should receive 2 doses in the following year.
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Adverse Events After Receipt of tIV
Children
Studies support the safety of annual TIV in children and 
adolescents. The largest published postlicensure population-
based study assessed TIV safety in 251,600 children aged <18 
years, (including 8,476 vaccinations in children aged 6–23 
months) through the Vaccine Safety Datalink (VSD), who 
were enrolled in one of five health maintenance organizations 
(HMOs) during 1993–1999. This study indicated no increase 
in clinically important medically attended events during the 2 
weeks after inactivated influenza vaccination compared with 
control periods 3–4 weeks before and after vaccination (180). 
A retrospective cohort study using VSD medical records data 
from 45,356 children aged 6–23 months provided additional 
evidence supporting overall safety of TIV in this age group. 
During the 2 weeks after vaccination, TIV was not associated 
with statistically significant increases in any clinically important 
medically attended events other than gastritis/duodenitis, and 
13 diagnoses, including acute upper respiratory illness, otitis 
media and asthma, were significantly less common (181). On 
chart review, most children with a diagnosis of gastritis/duo-
denitis had self-limited vomiting or diarrhea. The positive or 
negative associations between TIV and any of these diagnoses 
do not necessarily indicate a causal relationship (181).
In a study of 791 healthy children aged 1–15 years, postvac-
cination fever was noted among 12% of those aged 1–5 years, 
5% among those aged 6–10 years, and 5% among those aged 
11–15 years (87). Fever, malaise, myalgia, and other systemic 
symptoms that can occur after vaccination with inactivated 
vaccine most often affect persons who have had no previous 
exposure to the influenza virus antigens in the vaccine (e.g., 
young children) (182,183). These reactions begin 6–12 hours 
after vaccination and can persist for 1–2 days. Data about 
potential adverse events among children after influenza vacci-
nation are available from the Vaccine Adverse Event Reporting 
System (VAERS). Because of the limitations of passive report-
ing systems, determining causality for specific types of adverse 
events usually is not possible using VAERS data alone.
Published reviews of VAERS reports submitted after admin-
istration of TIV to children aged 6–23 months indicated that 
the most frequently reported adverse events were fever, rash, 
injection-site reactions, and seizures; the majority of the limited 
number of reported seizures appeared to be febrile (184,185). 
Seizure and fever were the leading serious adverse events 
(SAEs), defined using standard criteria, reported to VAERS 
in these studies (184,185); further investigation in VSD did 
not confirm an association with febrile seizures as identified 
in VAERS (181).
Adults
In placebo-controlled studies among adults, the most frequent 
side effect of vaccination was soreness at the vaccination site 
(affecting 10%–64% of patients) that lasted <2 days (186,187). 
These local reactions typically were mild and rarely interfered 
with the recipients’ ability to conduct usual daily activities. 
Placebo-controlled trials demonstrate that among older 
persons and healthy young adults, administration of TIV is 
not associated with higher rates for systemic symptoms (e.g., 
fever, malaise, myalgia, and headache) when compared with 
placebo injections (121,134,186–188). One prospective cohort 
study found that the rate of adverse events was similar among 
hospitalized persons who either were aged >65 years or were 
aged 18–64 years and had one or more chronic medical con-
ditions compared with outpatients (158). Adverse events in 
adults aged >18 years reported to VAERS during 1990–2005 
were analyzed. The most common adverse events reported to 
VAERS in adults included injection-site reactions, pain, fever, 
myalgia, and headache. The VAERS review identified no new 
safety concerns. In clinical trials, SAEs were reported to occur 
after vaccination with TIV at a rate of <1%. A small propor-
tion (14%) of the TIV VAERS reports in adults were classified 
as SAEs, without assessment of causality. The most common 
SAE reported after TIV in VAERS in adults was Guillain-Barré 
Syndrome (GBS) (189). The potential association between TIV 
and GBS has been an area of ongoing research (see Guillain-
Barré Syndrome and TIV).
Pregnant Women and neonates
FDA has classified TIV as a “Pregnancy Category C” medi-
cation, indicating that adequate animal reproduction studies 
have not been conducted.. Available data indicate that influ-
enza vaccine does not cause fetal harm when administered to 
a pregnant woman or affect reproductive capacity. One study 
of approximately 2,000 pregnant women who received TIV 
during pregnancy demonstrated no adverse fetal effects and 
no adverse effects during infancy or early childhood (190). 
A matched case-control study of 252 pregnant women who 
received TIV within the 6 months before delivery determined 
no adverse events after vaccination among pregnant women 
and no difference in pregnancy outcomes compared with 826 
pregnant women who were not vaccinated (148). During 
2000–2003, an estimated 2 million pregnant women were 
vaccinated, and only 20 adverse events among women who 
received TIV were reported to VAERS during this time, 
including nine injection-site reactions and eight systemic reac-
tions (e.g., fever, headache, and myalgias). In addition, three 
miscarriages were reported, but these were not known to be 
causally related to vaccination (191). Similar results have been 
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reported in certain smaller studies (147,149,192), and a recent 
international review of data on the safety of TIV concluded 
that no evidence exists to suggest harm to the fetus (193). The 
rate of adverse events associated with TIV was similar to the 
rate of adverse events among pregnant women who received 
pneumococcal polysaccharide vaccine in one small randomized 
controlled trial in Bangladesh, and no severe adverse events 
were reported in any study group (154).
Persons with Chronic Medical Conditions 
In a randomized cross-over study of children and adults with 
asthma, no increase in asthma exacerbations was reported for 
either age group (194), and two additional studies also have 
indicated no increase in wheezing among vaccinated asth-
matic children (114) or adults (195). One study reported that 
20%–28% of children with asthma aged 9 months–18 years 
had local pain and swelling at the site of influenza vaccina-
tion (104), and another study reported that 23% of children 
aged 6 months–4 years with chronic heart or lung disease had 
local reactions (93). A blinded, randomized, cross-over study 
of 1,952 adults and children with asthma demonstrated that 
only self-reported “body aches” were reported more frequently 
after TIV (25%) than placebo-injection (21%) (194). However, 
a placebo-controlled trial of TIV indicated no difference in 
local reactions among 53 children aged 6 months–6 years with 
high-risk medical conditions or among 305 healthy children 
aged 3–12 years (97).
Among children with high-risk medical conditions, one 
study of 52 children aged 6 months–3 years reported fever 
among 27% and irritability and insomnia among 25% (93); 
and a study among 33 children aged 6–18 months reported 
that one child had irritability and one had a fever and seizure 
after vaccination (196). No placebo comparison group was 
used in these studies.
Immunocompromised Persons
Data demonstrating safety of TIV for HIV-infected per-
sons are limited, but no evidence exists that vaccination has 
a clinically important impact on HIV infection or immuno-
competence. One study demonstrated a transient (i.e., 2–4 
week) increase in HIV RNA (ribonucleic acid) levels in one 
HIV-infected person after influenza virus infection (197). 
Studies have demonstrated a transient increase in replication 
of HIV-1 in the plasma or peripheral blood mononuclear 
cells of HIV-infected persons after vaccine administration 
(138,198). However, more recent and better-designed studies 
have not documented a substantial increase in the replication 
of HIV (199–202). CD4+ T-lymphocyte cell counts or pro-
gression of HIV disease have not been demonstrated to change 
substantially after influenza vaccination among HIV-infected 
persons compared with unvaccinated HIV-infected persons 
(138,203). Limited information is available about the effect 
of antiretroviral therapy on increases in HIV RNA levels after 
either natural influenza virus infection or influenza vaccina-
tion (52,204).
Data are similarly limited for persons with other immuno-
compromising conditions. In small studies, vaccination did not 
affect allograft function or cause rejection episodes in recipients 
of kidney transplants (141,142), heart transplants (143), or 
liver transplants (144).
Immediate Hypersensitivity Reactions 
after Influenza Vaccines
Vaccine components can rarely cause allergic reactions, also 
called immediate hypersensitivity reactions, among certain 
recipients. Immediate hypersensitivity reactions are mediated 
by preformed immunoglobulin E (IgE) antibodies against 
a vaccine component and usually occur within minutes to 
hours of exposure (205). Symptoms of immediate hypersen-
sitivity range from mild urticaria (hives) and angioedema to 
anaphylaxis. Anaphylaxis is a severe life-threatening reaction 
that involves multiple organ systems and can progress rapidly. 
Symptoms and signs of anaphylaxis can include but are not 
limited to generalized urticaria, wheezing, swelling of the 
mouth and throat, difficulty breathing, vomiting, hypotension, 
decreased level of consciousness, and shock. Minor symp-
toms such as red eyes or hoarse voice also might be present 
(179,205–208).
Allergic reactions might be caused by the vaccine antigen, 
residual animal protein, antimicrobial agents, preservatives, 
stabilizers, or other vaccine components (209). Manufacturers 
use a variety of compounds to inactivate influenza viruses and 
add antibiotics to prevent bacterial growth. Package inserts 
for specific vaccines of interest should be consulted for addi-
tional information. ACIP has recommended that all vaccine 
providers should be familiar with the office emergency plan 
and be certified in cardiopulmonary resuscitation (179). The 
Clinical Immunization Safety Assessment (CISA) network, a 
collaboration between CDC and six medical research centers 
with expertise in vaccination safety, has developed an algorithm 
to guide evaluation and revaccination decisions for persons 
with suspected immediate hypersensitivity after vaccination 
(205).
Immediate hypersensitivity reaction after TIV and LAIV are 
rare. A VSD study of children aged <18 years in four HMOs 
during 1991–1997 estimated the overall risk of postvaccina-
tion anaphylaxis to be less than 1 case per 500,000 doses 
administered and in this study no cases were identified in 
TIV recipients (210). Reports of anaphylaxis occurring after 
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receipt of TIV and LAIV in adults have rarely been reported 
to VAERS (189).
Some immediate hypersensitivity reactions after TIV or 
LAIV are caused by the presence of residual egg protein in 
the vaccines (211). Although influenza vaccines contain only 
a limited quantity of egg protein, this protein can induce 
immediate hypersensitivity reactions among persons who have 
severe egg allergy. Asking persons if they can eat eggs without 
adverse effects is a reasonable way to determine who might 
be at risk for allergic reactions from receiving influenza vac-
cines (179). Persons who have had symptoms such as hives or 
swelling of the lips or tongue, or who have experienced acute 
respiratory distress after eating eggs, should consult a physi-
cian for appropriate evaluation to help determine if future 
influenza vaccine should be administered. Persons who have 
documented (IgE)-mediated hypersensitivity to eggs, includ-
ing those who have had occupational asthma related to egg 
exposure or other allergic responses to egg protein, also might 
be at increased risk for allergic reactions to influenza vaccine, 
and consultation with a physician before vaccination should 
be considered (212–214). A regimen has been developed for 
administering influenza vaccine to asthmatic children with 
severe disease and egg hypersensitivity (213).
Hypersensitivity reactions to other vaccine components also 
can rarely occur. Although exposure to vaccines containing 
thimerosal can lead to hypersensitivity (215), the majority 
of patients do not have reactions to thimerosal when it is 
administered as a component of vaccines, even when patch 
or intradermal tests for thimerosal indicate hypersensitivity 
(216,217). When reported, hypersensitivity to thimerosal 
typically has consisted of local delayed hypersensitivity reac-
tions (216).
ocular and Respiratory Symptoms 
after tIV
Ocular or respiratory symptoms have occasionally been 
reported within 24 hours after TIV administration, but these 
symptoms typically are mild and resolve quickly without spe-
cific treatment. In some trials conducted in the United States, 
ocular or respiratory symptoms included red eyes (<1%–6%), 
cough (1%–7%), wheezing (1%), and chest tightness (1%–
3%) (207,208,218–220). However, most of these trials were 
not placebo-controlled, and causality cannot be determined. 
In addition, ocular and respiratory symptoms are features of a 
variety of respiratory illnesses and seasonal allergies that would 
be expected to occur coincidentally among vaccine recipients 
unrelated to vaccination. A placebo-controlled vaccine effec-
tiveness study among young adults found that 2% of persons 
who received the 2006–07 formulation of Fluzone (Sanofi 
Pasteur) reported red eyes compared with none of the controls 
(p = 0.03) (221). A similar trial conducted during the 2005–06 
influenza season found that 3% of Fluzone recipients reported 
red eyes compared with 1% of placebo recipients; however the 
difference was not statistically significant (222) .
Oculorespiratory syndrome (ORS), an acute, self-limited 
reaction to TIV with prominent ocular and respiratory 
symptoms, was first described during the 2000–01 influenza 
season in Canada. The initial case-definition for ORS was the 
onset of one or more of the following within 2–24 hours after 
receiving TIV: bilateral red eyes and/or facial edema and/or 
respiratory symptoms (coughing, wheezing, chest tightness, 
difficulty breathing, sore throat, hoarseness or difficulty swal-
lowing, cough, wheeze, chest tightness, difficulty breathing, 
sore throat, or facial swelling) (223). ORS was first described 
in Canada and strongly associated with one vaccine preparation 
(Fluviral S/F, Shire Biologics, Quebec, Canada) not available 
in the United States during the 2000–01 influenza season 
(224). Subsequent investigations identified persons with ocular 
or respiratory symptoms meeting an ORS case-definition in 
safety monitoring systems and trials that had been conducted 
before 2000 in Canada, the United States, and several European 
countries (225–227).
The cause of ORS has not been established; however studies 
suggest the reaction is not IgE-mediated (228). After changes in 
the manufacturing process of the vaccine preparation associated 
with ORS during 2000–01, the incidence of ORS in Canada 
was greatly reduced (226). In one placebo-controlled study, 
only hoarseness, cough, and itchy or sore eyes (but not red eyes) 
were significantly associated with a reformulated Fluviral prepa-
ration. These findings indicated that ORS symptoms following 
use of the reformulated vaccine were mild, resolved within 24 
hours, and might not typically be of sufficient concern to cause 
vaccine recipients to seek medical care (229).
Ocular and respiratory symptoms reported after TIV admin-
istration, including ORS, have some similarities with immedi-
ate hypersensitivity reactions. One study indicated that the risk 
for ORS recurrence with subsequent vaccination is low, and 
persons with ocular or respiratory symptoms (e.g., bilateral 
red eyes, cough, sore throat, or hoarseness) after TIV that did 
not involve the lower respiratory tract have been revaccinated 
without reports of SAEs after subsequent exposure to TIV 
(230). VAERS routinely monitors for adverse events such as 
ocular or respiratory symptoms after receipt of TIV.
Contraindications and Precautions for 
Use of tIV
TIV is contraindicated and should not be administered to 
persons known to have anaphylactic hypersensitivity to eggs or 
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to other components of the influenza vaccine unless the recipi-
ent has been desensitized. Prophylactic use of antiviral agents 
is an option for preventing influenza among such persons. 
Information about vaccine components is located in package 
inserts from each manufacturer. Persons with moderate to 
severe acute febrile illness usually should not be vaccinated until 
their symptoms have abated. Moderate or severe acute illness 
with or without fever is a precaution§ for TIV. GBS within 6 
weeks following a previous dose of influenza vaccine is consid-
ered to be a precaution for use of influenza vaccines.
Revaccination in Persons Who 
Experienced ocular or Respiratory 
Symptoms After tIV
When assessing whether a patient who experienced ocular 
and respiratory symptoms should be revaccinated, provid-
ers should determine if concerning signs and symptoms of 
Ig-E mediated immediate hypersensitivity are present (see 
Immediate Hypersensitivity after Influenza Vaccines). Health-
care providers who are unsure whether symptoms reported or 
observed after TIV represent an IgE-mediated hypersensitivity 
immune response should seek advice from an allergist/immu-
nologist. Persons with symptoms of possible IgE-mediated 
hypersensitivity after TIV should not receive influenza vac-
cination unless hypersensitivity is ruled out or revaccination 
is administered under close medical supervision (205).
Ocular or respiratory symptoms observed after TIV often are 
coincidental and unrelated to TIV administration, as observed 
among placebo recipients in some randomized controlled stud-
ies. Determining whether ocular or respiratory symptoms are 
coincidental or related to possible ORS might not be possible. 
Persons who have had red eyes, mild upper facial swelling, or 
mild respiratory symptoms (e.g., sore throat, cough, or hoarse-
ness) after TIV without other concerning signs or symptoms of 
hypersensitivity can receive TIV in subsequent seasons without 
further evaluation. Two studies showed that persons who had 
symptoms of ORS after TIV were at a higher risk for ORS after 
subsequent TIV administration; however, these events usually 
were milder than the first episode (230,231).
Guillain-Barré Syndrome and tIV
The annual incidence of GBS is 10–20 cases per 1 million 
adults (232). Substantial evidence exists that multiple infec-
tious illnesses, most notably Campylobacter jejuni gastroin-
testinal infections and upper respiratory tract infections, are 
associated with GBS (233–235). A recent study identified 
serologically confirmed influenza virus infection as a trigger 
of GBS, with time from onset of influenza illness to GBS of 
3–30 days. The estimated frequency of influenza-related GBS 
was four to seven times higher than the frequency that has been 
estimated for influenza-vaccine–associated GBS (236).
The 1976 swine influenza vaccine was associated with an 
increased frequency of GBS, estimated at one additional 
case of GBS per 100,000 persons vaccinated (237,238). The 
risk for influenza-vaccine–associated GBS was higher among 
persons aged >25 years than among persons aged <25 years 
(239). However, obtaining epidemiologic evidence for a small 
increase in risk for a rare condition with multiple causes is dif-
ficult, and no evidence consistently exists for a causal relation 
between subsequent vaccines prepared from other influenza 
viruses and GBS.
None of the studies conducted using influenza vaccines 
other than the 1976 swine influenza vaccine has demonstrated 
a substantial increase in GBS associated with influenza vac-
cines. During three of four influenza seasons studied during 
1977–1991, the overall relative risk estimates for GBS after 
influenza vaccination were not statistically significant in any of 
these studies (240–242). However, in a study of the 1992–93 
and 1993–94 seasons, the overall relative risk for GBS was 1.7 
(CI = 1.0–2.8; p = 0.04) during the 6 weeks after vaccination, 
representing approximately one additional case of GBS per 1 
million persons vaccinated; the combined number of GBS 
cases peaked 2 weeks after vaccination (238). Results of a study 
that examined health-care data from Ontario, Canada, during 
1992–2004 demonstrated a small but statistically significant 
temporal association between receiving influenza vaccination 
and subsequent hospital admission for GBS. However, no 
increase in cases of GBS at the population level was reported 
after introduction of a mass public influenza vaccination pro-
gram in Ontario beginning in 2000 (243). Data from VAERS 
have documented decreased reporting of GBS occurring 
after vaccination across age groups over time, despite overall 
increased reporting of other non-GBS conditions occurring 
after administration of influenza vaccine (237). Published 
data from the United Kingdom’s General Practice Research 
Database (GPRD) found influenza vaccine to be associated 
with a decreased risk for GBS, although whether this was 
associated with protection against influenza or confounding 
because of a “healthy vaccinee” (e.g., healthier persons might 
be more likely to be vaccinated and also be at lower risk for 
GBS) (244) is unclear. A separate GPRD analysis found no 
association between vaccination and GBS for a 9-year period; 
only three cases of GBS occurred within 6 weeks after admin-
istration of influenza vaccine (245). A third GPRD analysis 
found that GBS was associated with recent ILI, but not influ-
enza vaccination (246).
§ A precaution is a condition in a recipient that might increase the risk for a 
serious adverse reaction or that might compromise the ability of the vaccine to 
produce immunity (179).
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The estimated risk for GBS (on the basis of the few studies 
that have demonstrated an association between vaccination 
and GBS) is low (i.e., approximately one additional case per 
1 million persons vaccinated). The potential benefits of influ-
enza vaccination in preventing serious illness, hospitalization, 
and death substantially outweigh these estimates of risk for 
vaccine-associated GBS. No evidence indicates that the case-
fatality ratio for GBS differs among vaccinated persons and 
those not vaccinated.
Use of tIV Among Patients with a 
History of GBS
The incidence of GBS among the general population is 
low, but persons with a history of GBS have a substantially 
greater likelihood of subsequently experiencing GBS than 
persons without such a history (232). Thus, the likelihood of 
coincidentally experiencing GBS after influenza vaccination 
is expected to be greater among persons with a history of 
GBS than among persons with no history of this syndrome. 
Whether influenza vaccination specifically might increase the 
risk for recurrence of GBS is unknown. Among 311 patients 
with GBS who responded to a survey, 11 (4%) reported some 
worsening of symptoms after influenza vaccination; however, 
some of these patients had received other vaccines at the same 
time, and recurring symptoms were generally mild (247). 
However, as a precaution, persons who are not at high risk 
for severe influenza complications and who are known to 
have experienced GBS within 6 weeks generally should not 
be vaccinated. As an alternative, physicians might consider 
using influenza antiviral chemoprophylaxis for these persons. 
Although data are limited, the established benefits of influenza 
vaccination might outweigh the risks for many persons who 
have a history of GBS and who also are at high risk for severe 
complications from influenza.
Vaccine Preservative (thimerosal) in 
Multidose Vials of tIV
Thimerosal, a mercury-containing antibacterial compound, 
has been used as a preservative in vaccines and other medi-
cations since the 1930s (248) and is used in multidose vial 
preparations of TIV to reduce the likelihood of bacterial 
growth. No scientific evidence indicates that thimerosal in 
vaccines, including influenza vaccines, is a cause of adverse 
events other than occasional local hypersensitivity reactions 
in vaccine recipients. In addition, no scientific evidence exists 
that thimerosal-containing vaccines are a cause of adverse 
events among children born to women who received vaccine 
during pregnancy. The weight of accumulating evidence does 
not suggest an increased risk for neurodevelopment disorders 
from exposure to thimerosal-containing vaccines (249–258). 
The U.S. Public Health Service and other organizations have 
recommended that efforts be made to eliminate or reduce 
the thimerosal content in vaccines as part of a strategy to 
reduce mercury exposures from all sources (249,250,259) 
Also, continuing public concerns about exposure to mercury 
in vaccines has been viewed as a potential barrier to achiev-
ing higher vaccine coverage levels and reducing the burden 
of vaccine-preventable diseases. Since mid-2001, vaccines 
routinely recommended for infants aged <6 months in the 
United States have been manufactured either without or with 
greatly reduced (trace) amounts of thimerosal. As a result, 
a substantial reduction in the total mercury exposure from 
vaccines for infants and children already has been achieved 
(179)). ACIP and other federal agencies and professional 
medical organizations continue to support efforts to provide 
thimerosal-preservative–free vaccine options.
The benefits of influenza vaccination for all recommended 
groups, including pregnant women and young children, 
outweigh concerns on the basis of a theoretical risk from 
thimerosal exposure through vaccination. The risks for severe 
illness from influenza virus infection are elevated among both 
young children and pregnant women, and vaccination has been 
demonstrated to reduce the risk for severe influenza illness and 
subsequent medical complications. In contrast, no scientifically 
conclusive evidence has demonstrated harm from exposure to 
vaccine containing thimerosal preservative. For these reasons, 
persons recommended to receive TIV may receive any age- and 
risk factor–appropriate vaccine preparation, depending on 
availability. An analysis of VAERS reports found no difference 
in the safety profile of preservative-containing compared with 
preservative-free TIV vaccines in infants aged 6–23 months 
(184).
Nonetheless, as of May 2009, some states have enacted 
legislation banning the administration of vaccines containing 
mercury; the provisions defining mercury content vary (260). 
LAIV and many of the single-dose vial or syringe preparations 
of TIV are thimerosal-free, and the number of influenza vac-
cine doses that do not contain thimerosal as a preservative 
is expected to increase (Table 2). However, these laws might 
present a barrier to vaccination unless influenza vaccines that 
do not contain thimerosal as a preservative are easily available 
in those states.
The U.S. vaccine supply for infants and pregnant women 
is in a period of transition as manufacturers expand the avail-
ability of thimerosal-reduced or thimerosal-free vaccine to 
reduce the cumulative exposure of infants to mercury. Other 
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environmental sources of mercury exposure are more difficult 
or impossible to avoid or eliminate (249).
LAIV Dosage, Administration, and 
Storage
Each dose of LAIV contains the same three vaccine anti-
gens used in TIV. However, the antigens are constituted as 
live, attenuated, cold-adapted, temperature-sensitive vaccine 
viruses. Providers should refer to the package insert, which 
contains additional information about the formulation of 
this vaccine and other vaccine components. LAIV does not 
contain thimerosal. LAIV is made from attenuated viruses that 
are able to replicate efficiently only at temperatures present in 
the nasal mucosa. LAIV does not cause systemic symptoms of 
influenza in vaccine recipients, although a minority of recipi-
ents experience nasal congestion or fever, which is probably a 
result of effects of intranasal vaccine administration or local 
viral replication or fever (261).
LAIV is intended for intranasal administration only and 
should not be administered by the intramuscular, intradermal, 
or intravenous route. LAIV is not licensed for vaccination of 
children aged <2 years or adults aged >49 years. LAIV is sup-
plied in a prefilled, single-use sprayer containing 0.2 mL of 
vaccine. Approximately 0.1 mL (i.e., half of the total sprayer 
contents) is sprayed into the first nostril while the recipient 
is in the upright position. An attached dose-divider clip is 
removed from the sprayer to administer the second half of 
the dose into the other nostril. LAIV is shipped at 35°F–46°F 
(2°C–8°C). LAIV should be stored at 35°F–46°F (2°C–8°C) on 
receipt and can remain at that temperature until the expiration 
date is reached (261). Vaccine prepared for a previous influenza 
season should not be administered to provide protection for 
any subsequent season.
Shedding, transmission, and Stability 
of Vaccine Viruses
Available data indicate that both children and adults vac-
cinated with LAIV can shed vaccine viruses after vaccination, 
although in lower amounts than occur typically with shedding 
of wild-type influenza viruses. In rare instances, shed vaccine 
viruses can be transmitted from vaccine recipients to unvac-
cinated persons. However, serious illnesses have not been 
reported among unvaccinated persons who have been infected 
inadvertently with vaccine viruses.
One study of 197 children aged 8–36 months in a child 
care center assessed transmissibility of vaccine viruses from 
98 vaccinated children to the other 99 unvaccinated children; 
80% of vaccine recipients shed one or more virus strains (mean 
duration: 7.6 days). One influenza type B vaccine strain isolate 
was recovered from a placebo recipient and was confirmed to 
be vaccine-type virus. The type B isolate retained the cold-
adapted, temperature-sensitive, attenuated phenotype, and 
it possessed the same genetic sequence as a virus shed from a 
vaccine recipient who was in the same play group. The placebo 
recipient from whom the influenza type B vaccine strain was 
isolated had symptoms of a mild upper respiratory illness but 
did not experience any serious clinical events. The estimated 
probability of acquiring vaccine virus after close contact with 
a single LAIV recipient in this child care population was 
1%–2% (262).
Studies assessing whether vaccine viruses are shed have been 
based on viral cultures or PCR detection of vaccine viruses in 
nasal aspirates from persons who have received LAIV. Among 
345 subjects aged 5–49 years, 30% had detectable virus in 
nasal secretions obtained by nasal swabbing after receiving 
LAIV. The duration of virus shedding and the amount of 
virus shed was inversely correlated with age, and maximal 
shedding occurred within 2 days of vaccination. Symptoms 
reported after vaccination, including runny nose, headache, 
and sore throat, did not correlate with virus shedding (263). 
Other smaller studies have reported similar findings (264,265). 
Vaccine strain virus was detected from nasal secretions in one 
(2%) of 57 HIV-infected adults who received LAIV, none 
of 54 HIV-negative participants (266), and three (13%) of 
23 HIV-infected children compared with seven (28%) of 25 
children who were not HIV-infected (267). No participants in 
these studies had detectable virus beyond 10 days after receipt 
of LAIV. The possibility of person-to-person transmission of 
vaccine viruses was not assessed in these studies (264–267).
In clinical trials, viruses isolated from vaccine recipients have 
retained attenuated phenotypes. In one study, nasal and throat 
swab specimens were collected from 17 study participants for 2 
weeks after vaccine receipt (268). Virus isolates were analyzed 
by multiple genetic techniques. All isolates retained the LAIV 
genotype after replication in the human host, and all retained 
the cold-adapted and temperature-sensitive phenotypes. A 
study conducted in a child care setting demonstrated that 
limited genetic change occurred in the LAIV strains following 
replication in the vaccine recipients (269).
Immunogenicity, Efficacy, and 
Effectiveness of LAIV
LAIV virus strains replicate primarily in nasopharyngeal epi-
thelial cells. The protective mechanisms induced by vaccination 
with LAIV are not understood completely but appear to involve 
both serum and nasal secretory antibodies. The immunogenic-
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ity of the approved LAIV has been assessed in multiple studies 
conducted among children and adults (270–276).
Healthy Children
A randomized, double-blind, placebo-controlled trial among 
1,602 healthy children aged 15–71 months assessed the effi-
cacy of LAIV against culture-confirmed influenza during two 
seasons (277,278). This trial included a subset of children aged 
60–71 months who received 2 doses in the first season. During 
season one (1996–97), when vaccine and circulating virus 
strains were well-matched, efficacy against culture-confirmed 
influenza was 94% for participants who received 2 doses of 
LAIV separated by >6 weeks, and 89% for those who received 
1 dose. During season two (1997–98), when the A (H3N2) 
component in the vaccine was not well-matched with circu-
lating virus strains, efficacy (1 dose) was 86%, for an overall 
efficacy for two influenza seasons of 92%. Receipt of LAIV 
also resulted in 21% fewer febrile illnesses and a significant 
decrease in acute otitis media requiring antibiotics (277,279). 
Other randomized, placebo-controlled trials demonstrating the 
efficacy of LAIV in young children against culture-confirmed 
influenza include a study conducted among children aged 
6–35 months attending child care centers during consecu-
tive influenza seasons (280) in which 85%–89% efficacy was 
observed, and a study conducted among children aged 12–36 
months living in Asia during consecutive influenza seasons 
in which 64%–70% efficacy was documented (281). In one 
community-based, nonrandomized open-label study, reduc-
tions in MAARI were observed among children who received 
1 dose of LAIV during the 1990–00 and 2000–01 influenza 
seasons even though antigenically drifted influenza A/H1N1 
and B viruses were circulating during that season (282). LAIV 
efficacy in preventing laboratory-confirmed influenza also has 
been demonstrated in studies comparing the efficacy of LAIV 
with TIV rather than with a placebo (see Comparisons of LAIV 
and TIV Efficacy or Effectiveness).
Healthy Adults
A randomized, double-blind, placebo-controlled trial of 
LAIV effectiveness among 4,561 healthy working adults aged 
18–64 years assessed multiple endpoints, including reductions 
in self-reported respiratory tract illness without laboratory 
confirmation, work loss, health-care visits, and medication use 
during influenza outbreak periods . The study was conducted 
during the 1997–98 influenza season, when the vaccine and 
circulating A (H3N2) strains were not well-matched. The 
frequency of febrile illnesses was not significantly decreased 
among LAIV recipients compared with those who received pla-
cebo. However, vaccine recipients had significantly fewer severe 
febrile illnesses (19% reduction) and febrile upper respiratory 
tract illnesses (24% reduction), and significant reductions in 
days of illness, days of work lost, days with health-care–provider 
visits, and use of prescription antibiotics and over-the-counter 
medications (283). Efficacy against culture-confirmed influ-
enza in a randomized, placebo-controlled study was 57% in the 
2004–05 influenza season and 43% in the 2005–06 influenza 
season, although efficacy in these studies was not demonstrated 
to be significantly greater than placebo (221,222).
Adverse Events after Receipt of LAIV
Healthy Children Aged 2–18 Years
In a subset of healthy children aged 60–71 months from one 
clinical trial, certain signs and symptoms were reported more 
often after the first dose among LAIV recipients (n = 214) than 
among placebo recipients (n = 95), including runny nose (48% 
and 44%, respectively); headache (18% and 12%, respectively); 
vomiting (5% and 3%, respectively); and myalgias (6% and 
4%, respectively) (277). However, these differences were not 
statistically significant. In other trials, signs and symptoms 
reported after LAIV administration have included runny 
nose or nasal congestion (20%–75%), headache (2%–46%), 
fever (0–26%), vomiting (3%–13%), abdominal pain (2%), 
and myalgias (0–21%) (270,272,273,280,284–287). These 
symptoms were associated more often with the first dose and 
were self-limited. A placebo-controlled trial in 9,689 children 
aged 1–17 years assessed prespecified medically attended out-
comes during the 42 days after vaccination (286). Following 
>1,500 statistical analyses in the 42 days after LAIV, elevated 
risks that were biologically plausible were observed for the 
following conditions: asthma, upper respiratory infection, 
musculoskeletal pain, otitis media with effusion, and adenitis/
adenopathy. The increased risk for wheezing events after LAIV 
was observed among children aged 18–35 months (RR: 4.06; 
90% CI = 1.3–17.9). In this study, the rate of SAEs was 0.2% 
in LAIV and placebo recipients; none of the SAEs was judged 
to be related to the vaccine by the study investigators (286).
In a randomized trial published in 2007, LAIV and TIV 
were compared among children aged 6–59 months (288). 
Children with medically diagnosed or treated wheezing within 
42 days before enrollment or with a history of severe asthma 
were excluded from this study. Among children aged 24–59 
months who received LAIV, the rate of medically significant 
wheezing, using a prespecified definition, was not greater 
compared with those who received TIV (288). Wheezing was 
observed more frequently among younger LAIV recipients 
aged 6–23 months in this study; LAIV is not licensed for this 
age group. In a previous randomized placebo-controlled safety 
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trial among children aged 12 months–17 years without a his-
tory of asthma by parental report, an elevated risk for asthma 
events (RR: 4.1; CI = 1.3–17.9) was documented among 728 
children aged 18–35 months who received LAIV. Of the 16 
children with asthma-related events in this study, seven had a 
history of asthma on the basis of subsequent medical record 
review. None required hospitalization, and elevated risks for 
asthma were not observed in other age groups (286).
Another study was conducted among >11,000 children 
aged 18 months–18 years in which 18,780 doses of vaccine 
were administered for 4 years. For children aged 18 months–4 
years, no increase was reported in asthma visits 0–15 days 
after vaccination compared with the prevaccination period. A 
significant increase in asthma events was reported 15–42 days 
after vaccination, but only in vaccine year 1 (289). A 4-year, 
open-label field trial study assessed LAIV safety of more than 
2000 doses administered to children aged 18 months–18 years 
with a history of intermittent wheeze who were otherwise 
healthy. Among these children, no increased risk was reported 
for medically attended acute respiratory illnesses, including 
acute asthma exacerbation, during the 0–14 or 0–42 days after 
LAIV compared with the pre- and postvaccination reference 
periods (290).
Initial data from VAERS during 2007–2008, following 
ACIP’s recommendation for LAIV use in healthy children aged 
2–4 years, did not suggest a concern for wheezing after LAIV 
in young children. However data also suggest uptake of LAIV 
was limited, and safety monitoring for wheezing events after 
LAIV is ongoing (CDC, unpublished data, 2008).
Adults Aged 19–49 Years
Among adults, runny nose or nasal congestion (28%–78%), 
headache (16%–44%), and sore throat (15%–27%) have been 
reported more often among vaccine recipients than placebo 
recipients (277,291). In one clinical trial among a subset of 
healthy adults aged 18–49 years, signs and symptoms reported 
significantly more often (p<0.05) among LAIV recipients 
(n = 2,548) than placebo recipients (n = 1,290) within 7 days 
after each dose included cough (14% and 11%, respectively), 
runny nose (45% and 27%, respectively), sore throat (28% 
and 17%, respectively), chills (9% and 6%, respectively), and 
tiredness/weakness (26% and 22%, respectively) (92). A review 
of 460 reports to VAERS after distribution of approximately 
2.5 million doses during the 2003–04 and 2004–05 influenza 
seasons did not indicate any new safety concerns (292). Few of 
the LAIV VAERS reports (9%) were SAEs; respiratory events 
were the most common conditions reported.
Persons at Higher Risk for Influenza-Related 
Complications
Limited data assessing the safety of LAIV use for certain 
groups at higher risk for influenza-related complications are 
available. In one study of 54 HIV-infected persons aged 18–58 
years and with CD4+ counts >200 cells/mm3 who received 
LAIV, no SAEs were reported during a 1-month follow-up 
period (266). Similarly, one study demonstrated no significant 
difference in the frequency of adverse events or viral shedding 
among HIV-infected children aged 1–8 years on effective 
antiretroviral therapy who were administered LAIV compared 
with HIV-uninfected children receiving LAIV (267). LAIV 
was well-tolerated among adults aged >65 years with chronic 
medical conditions (293). These findings suggest that persons 
at risk for influenza complications who have inadvertent 
exposure to LAIV would not have significant adverse events or 
prolonged viral shedding and that persons who have contact 
with persons at higher risk for influenza-related complications 
may receive LAIV.
Comparisons of LAIV and tIV Efficacy 
or Effectiveness
Both TIV and LAIV have been demonstrated to be effective 
in children and adults. However, data directly comparing the 
efficacy or effectiveness of these two types of influenza vaccines 
are limited and insufficient to identify whether one vaccine 
might offer a clear advantage over the other in certain settings 
or populations. Studies comparing the efficacy of TIV to that 
of LAIV have been conducted in a variety of settings and 
populations using several different outcomes. One random-
ized, double-blind, placebo-controlled challenge study that was 
conducted among 92 healthy adults aged 18–41 years assessed 
the efficacy of both LAIV and TIV in preventing influenza 
infection when challenged with wild-type strains that were anti-
genically similar to vaccine strains (294). The overall efficacy 
in preventing laboratory-documented influenza from all three 
influenza strains combined was 85% and 71%, respectively, 
when challenged 28 days after vaccination by viruses to which 
study participants were susceptible before vaccination. The dif-
ference in efficacy between the two vaccines was not statistically 
significant in this limited study. No additional challenges were 
conducted to assess efficacy at time points later than 28 days 
(294). In a randomized, double-blind, placebo-controlled trial 
that was conducted among young adults during the 2004–05 
influenza season, when the majority of circulating H3N2 
viruses were antigenically drifted from that season’s vaccine 
viruses, the efficacy of LAIV and TIV against culture-confirmed 
influenza was 57% and 77%, respectively. The difference in 
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efficacy was not statistically significant and was attributable 
primarily to a difference in efficacy against influenza B (222). A 
similar study conducted during the 2005–06 influenza season 
found no significant difference in vaccine efficacy (221).
A randomized controlled clinical trial conducted among chil-
dren aged 6–59 months during the 2004–05 influenza season 
demonstrated a 55% reduction in cases of culture-confirmed 
influenza among children who received LAIV compared with 
those who received TIV (288). In this study, LAIV efficacy 
was higher compared with TIV against antigenically drifted 
viruses and well-matched viruses (288). An open-label, nonran-
domized, community-based influenza vaccine trial conducted 
during an influenza season when circulating H3N2 strains 
were poorly matched with strains contained in the vaccine also 
indicated that LAIV, but not TIV, was effective against anti-
genically drifted H3N2 strains during that influenza season. 
In this study, children aged 5–18 years who received LAIV had 
significant protection against laboratory-confirmed influenza 
(37%) and pneumonia and influenza events (50%) (295). A 
recent observational study conducted among military person-
nel aged 17–49 years over three influenza seasons indicated that 
persons who received TIV had a significantly lower incidence 
of health-care encounters resulting in diagnostic coding for 
pneumonia and influenza compared with those who received 
LAIV. However, among new recruits being vaccinated for the 
first time, the incidence of pneumonia- and influenza-coded 
health-care encounters among those received LAIV was similar 
to those receiving TIV (296).
Although LAIV is not licensed for use in persons with 
risk factors for influenza complications, certain studies have 
compared the efficacy of LAIV to TIV in these groups. LAIV 
provided 32% increased protection in preventing culture-con-
firmed influenza compared with TIV in one study conducted 
among children aged >6 years and adolescents with asthma 
(297) and 52% increased protection compared with TIV 
among children aged 6–71 months with recurrent respiratory 
tract infections (298).
Effectiveness of Vaccination for 
Decreasing transmission to Contacts
Decreasing transmission of influenza from caregivers and 
household contacts to persons at high risk might reduce ILI 
and complications among persons at high risk. Influenza 
virus infection and ILI are common among HCP (299–301). 
Influenza outbreaks have been attributed to low vaccination 
rates among HCP in hospitals and long-term–care facilities 
(302–304). One serosurvey demonstrated that 23% of HCP 
had serologic evidence of influenza virus infection during 
a single influenza season; the majority had mild illness or 
subclinical infection (299). Observational studies have dem-
onstrated that vaccination of HCP is associated with decreased 
deaths among nursing home patients (305,306). In one cluster-
randomized controlled trial that included 2,604 residents of 
44 nursing homes, significant decreases in mortality, ILI, and 
medical visits for ILI care were demonstrated among residents 
in nursing homes in which staff were offered influenza vac-
cination (coverage rate: 48%) compared with nursing homes 
in which staff were not provided with vaccination (coverage 
rate: 6%) (307). A review concluded that vaccination of HCP 
in settings in which patients also were vaccinated provided 
significant reductions in deaths among elderly patients from 
all causes and deaths from pneumonia (308).
Epidemiologic studies of community outbreaks of influenza 
demonstrate that school-aged children typically have the high-
est influenza illness attack rates, suggesting routine universal 
vaccination of children might reduce transmission to their 
household contacts and possibly others in the community. 
Results from certain studies have indicated that the benefits 
of vaccinating children might extend to protection of their 
adult contacts and to persons at risk for influenza complica-
tions in the community. However, these data are limited, and 
studies have not used laboratory-confirmed influenza as an 
outcome measure. A single-blinded, randomized controlled 
study conducted as part of a 1996–1997 vaccine effectiveness 
study demonstrated that vaccinating preschool-aged children 
with TIV reduced influenza-related morbidity among some 
household contacts (309). A randomized, placebo-controlled 
trial among children with recurrent respiratory tract infections 
demonstrated that members of families with children who had 
received LAIV were significantly less likely to have respiratory 
tract infections and reported significantly fewer workdays lost 
compared with families with children who received placebo 
(310). In nonrandomized community-based studies, admin-
istration of LAIV has been demonstrated to reduce MAARI 
(311,312) and ILI-related economic and medical consequences 
(e.g., workdays lost and number of health-care provider visits) 
among contacts of vaccine recipients (312). Households with 
children attending schools in which school-based LAIV vac-
cination programs had been established reported less ILI and 
fewer physician visits during peak influenza season compared 
with households with children in schools in which no LAIV 
vaccination had been offered. However a decrease in the overall 
rate of school absenteeism was not reported in communities 
in which LAIV vaccination was offered (312). During an 
influenza outbreak during the 2005–06 influenza season, 
countywide school-based influenza vaccination was associated 
with reduced absenteeism among elementary and high school 
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students in one county that implemented a school based vac-
cination program compared with another county without such 
a program (313). These community-based studies have not 
used laboratory-confirmed influenza as an outcome.
Some studies also have documented reductions in influenza 
illness among persons living in communities where focused 
programs for vaccinating children have been conducted. A 
community-based observational study conducted during the 
1968 pandemic using a univalent inactivated vaccine reported 
that a vaccination program targeting school-aged children 
(coverage rate: 86%) in one community reduced influenza 
rates within the community among all age groups compared 
with another community in which aggressive vaccination was 
not conducted among school-aged children (314). An obser-
vational study conducted in Russia demonstrated reductions 
in ILI among the community-dwelling elderly after imple-
mentation of a vaccination program using TIV for children 
aged 3–6 years (57% coverage achieved) and children and 
adolescents aged 7–17 years (72% coverage achieved) (315). 
In a nonrandomized community-based study conducted over 
three influenza seasons, 8%–18% reductions in the incidence 
of MAARI during the influenza season among adults aged 
>35 years were observed in communities in which LAIV was 
offered to all children aged >18 months (estimated coverage 
rate: 20%–25%) compared with communities that did not 
provide routine influenza vaccination programs for all children 
(311). In a subsequent influenza season, the same investigators 
documented a 9% reduction in MAARI rates during the influ-
enza season among persons aged 35–44 years in intervention 
communities, where coverage was estimated at 31% among 
school children. However, MAARI rates among persons aged 
>45 years were lower in the intervention communities regard-
less of the presence of influenza in the community, suggesting 
that lower rates could not be attributed to vaccination of school 
children against influenza (295).
The largest study to examine the community effects of 
increasing overall vaccine coverage was an ecologic study that 
described the experience in Ontario, Canada, which was the 
only province to implement a universal influenza vaccination 
program beginning in 2000. On the basis of models developed 
from administrative and viral surveillance data, influenza-
related mortality, hospitalizations, ED use, and physicians’ 
office visits decreased significantly more in Ontario after pro-
gram introduction than in other provinces, with the largest 
reductions observed in younger age groups (316).
Effectiveness of Influenza Vaccination 
When Circulating Influenza Virus 
Strains Differ from Vaccine Strains
Manufacturing trivalent influenza virus vaccines is a chal-
lenging process that takes 6–8 months to complete. Vaccination 
can provide reduced but substantial cross-protection against 
drifted strains in some seasons, including reductions in severe 
outcomes such as hospitalization. Usually one or more circulat-
ing viruses with antigenic changes compared with the vaccine 
strains are identified in each influenza season. In addition, two 
distinct lineages of influenza B viruses have co-circulated in 
recent years, and limited cross-protection is observed against 
the lineage not represented in the vaccine (48). However, assess-
ment of the clinical effectiveness of influenza vaccines cannot 
be determined solely by laboratory evaluation of the degree 
of antigenic match between vaccine and circulating strains. 
In some influenza seasons, circulating influenza viruses with 
significant antigenic differences predominate, and reductions 
in vaccine effectiveness sometimes are observed compared 
with seasons when vaccine and circulating strains are well-
matched,(107,121,125,173,222). However, even during years 
when vaccine strains were not antigenically well matched to 
circulating strains (the result of antigenic drift), substantial 
protection has been observed against severe outcomes, pre-
sumably because of vaccine-induced cross-reacting antibodies 
(121,125,222,283). For example, in one study conducted 
during the 2003–04 influenza season, when the predominant 
circulating strain was an influenza A (H3N2) virus that was 
antigenically different from that season’s vaccine strain, effec-
tiveness against laboratory-confirmed influenza illness among 
persons aged 50–64 years was 60% among healthy persons and 
48% among persons with medical conditions that increased 
the risk for influenza complications (125). An interim, within-
season analysis during the 2007–08 influenza season indicated 
that vaccine effectiveness was 44% overall, 54% among healthy 
persons aged 5–49 years, and 58% against influenza A, despite 
the finding that viruses circulating in the study area were pre-
dominately a drifted influenza A (H3N2) and an influenza B 
strain from a different lineage compared with vaccine strains 
(317). Among children, both TIV and LAIV provide pro-
tection against infection even in seasons when vaccines and 
circulating strains are not well-matched. Vaccine effectiveness 
against ILI was 49%–69% in two observational studies, and 
49% against medically attended, laboratory-confirmed influ-
enza in a case-control study conducted among young children 
during the 2003–04 influenza season, when a drifted influenza 
A (H3N2) strain predominated, based on viral surveillance data 
(102,106). However, continued improvements in collecting 
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representative circulating viruses and use of surveillance data to 
forecast antigenic drift are needed. Shortening manufacturing 
time to increase the time to identify good vaccine candidate 
strains from among the most recent circulating strains also is 
important. Data from multiple seasons that are collected in 
a consistent manner are needed to better understand vaccine 
effectiveness during seasons when circulating and vaccine virus 
strains are not well-matched.
Seasonal influenza vaccines are not expected to provide 
protection against novel influenza A (H1N1) virus infec-
tion because this novel strain hemagglutinin is substantially 
different from seasonal influenza A (H1N1). Preliminary 
immunologic data indicate that few persons have antibody 
that shows evidence of cross-reactivity against novel influenza 
A (H1N1) virus, and few show increases in antibody titer to 
novel influenza A (H1N1) virus after vaccination with the 
2007–08 or the 2008–09 seasonal influenza vaccines (318). 
Vaccines currently are being developed that are specific to novel 
influenza A (H1N1) virus.
Cost-Effectiveness of Influenza 
Vaccination
Economic studies of influenza vaccination are difficult to 
compare because they have used different measures of both 
costs and benefits (e.g., cost-only, cost-effectiveness, cost-
benefit, or cost-utility). However, most studies find that 
vaccination reduces or minimizes health care, societal, and 
individual costs and the productivity losses and absenteeism 
associated with influenza illness. One national study estimated 
the annual economic burden of seasonal influenza in the United 
States (using 2003 population and dollars) to be $87.1 billion, 
including $10.4 billion in direct medical costs (319).
Studies of influenza vaccination in the United States among 
persons aged >65 years have estimated substantial reductions 
in hospitalizations and deaths and overall societal cost savings 
(168,169). Studies comparing adults in different age groups 
also find that vaccination is economically beneficial. One study 
that compared the economic impact of vaccination among 
persons aged >65 years with those aged 15–64 years indicated 
that vaccination resulted in a net savings per quality-adjusted 
life year (QALY) and that the Medicare program saved costs 
of treating illness by paying for vaccination (320). A study 
of a larger population comparing persons aged 50–64 years 
with those aged >65 years estimated the cost-effectiveness of 
influenza vaccination to be $28,000 per QALY saved (in 2000 
dollars) in persons aged 50–64 years compared with $980 per 
QALY saved among persons aged >65 years (321).
Economic analyses among adults aged <65 years have 
reported mixed results regarding influenza vaccination. Two 
studies in the United States found that vaccination can reduce 
both direct medical costs and indirect costs from work absen-
teeism and reduced productivity (322,323). However, another 
U.S. study indicated no productivity and absentee savings in 
a strategy to vaccinate healthy working adults, although vac-
cination was still estimated to be cost-effective (324).
Cost analyses have documented the considerable financial 
burden of illness among children. In a study of 727 children 
conducted at a medical center during 2000–2004, the mean 
total cost of hospitalization for influenza-related illness was 
$13,159 ($39,792 for patients admitted to an intensive care 
unit and $7,030 for patients cared for exclusively on the 
wards) (325). A strategy that focuses on vaccinating children 
with medical conditions that confer a higher risk for influ-
enza complications are more cost-effective than a strategy of 
vaccinating all children (324). An analysis that compared the 
costs of vaccinating children of varying ages with TIV and 
LAIV indicated that costs per QALY saved increased with age 
for both vaccines. In 2003 dollars per QALY saved, costs for 
routine vaccination using TIV were $12,000 for healthy chil-
dren aged 6–23 months and $119,000 for healthy adolescents 
aged 12–17 years compared with $9,000 and $109,000 using 
LAIV, respectively (326). Economic evaluations of vaccinating 
children have demonstrated a wide range of cost estimates, but 
have generally found this strategy to be either cost-saving or 
cost-beneficial (327–330).
Economic analyses are sensitive to the vaccination venue, 
with vaccination in medical care settings incurring higher 
projected costs. In a published model, the mean cost (year 
2004 values) of vaccination was lower in mass vaccination 
($17.04) and pharmacy ($11.57) settings than in scheduled 
doctor’s office visits ($28.67) (331). Vaccination in nonmedi-
cal settings was projected to be cost saving for healthy adults 
aged >50 years and for high-risk adults of all ages. For healthy 
adults aged 18–49 years, preventing an episode of influenza 
would cost $90 if vaccination were delivered in a pharmacy 
setting, $210 in a mass vaccination setting, and $870 during 
a scheduled doctor’s office visit (331). Medicare payment rates 
in recent years have been less than the costs associated with 
providing vaccination in a medical practice (332).
Vaccination Coverage Levels
Continued annual monitoring is needed to determine the 
effects on vaccination coverage of vaccine supply delays and 
shortages, changes in influenza vaccination recommendations 
and target groups for vaccination, reimbursement rates for vac-
cine and vaccine administration, and other factors related to 
vaccination coverage among adults and children. One of the 
Healthy People 2010 objectives (objective no. 14-29a) includes 
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achieving an influenza vaccination coverage level of 90% for 
persons aged >65 years and among nursing home residents 
(333,334); new strategies to improve coverage are needed to 
achieve this objective (335,336). Increasing vaccination cov-
erage among persons who have high-risk conditions and are 
aged <65 years, including children at high risk, is the highest 
priority for expanding influenza vaccine use.
On the basis of the 2007 final data and the 2008 early release 
data from the National Health Interview Survey (NHIS), esti-
mated national influenza vaccine coverage during the 2006–07 
and 2007–08 influenza seasons increased minimally among 
persons aged >65 years and those aged 50–64 years (Table 3) 
and are only slightly lower than coverage levels observed before 
the 2004–05 vaccine shortage year (337–339). In the 2006–07 
and 2007–08 influenza seasons, estimated vaccination cover-
age levels among adults with high-risk conditions aged 18–49 
years were 25% and 30%, respectively, substantially lower than 
the Healthy People 2000 and Healthy People 2010 objectives of 
60% (Table 3) (333,334).
Studies conducted among children and adults indicate that 
opportunities to vaccinate persons at risk for influenza com-
plications (e.g., during hospitalizations for other causes) often 
are missed. In one study, 23% of children hospitalized with 
influenza and a comorbidity had a previous hospitalization 
during the preceding influenza vaccination season (340). In a 
study of hospitalized Medicare patients, only 31.6% were vac-
cinated before admission, 1.9% during admission, and 10.6% 
after admission (341). A study in New York City conducted 
during 2001–2005 among 7,063 children aged 6–23 months 
indicated that 2-dose vaccine coverage increased from 1.6% 
to 23.7% over time; however, although the average number of 
medical visits during which an opportunity to be vaccinated 
decreased during the course of the study from 2.9 to 2.0 per 
child, 55% of all visits during the final year of the study still 
represented a missed vaccination opportunity (342). Using 
standing orders in hospitals increases vaccination rates among 
hospitalized persons (343), and vaccination of hospitalized 
patients is safe and stimulates an appropriate immune response 
(158). In one survey, the strongest predictor of receiving vac-
cination was the survey respondent’s belief that he or she was 
in a high-risk group, based on data from one survey; however, 
many persons in high-risk groups did not know that they were 
in a group recommended for vaccination (344).
Reducing racial/ethnic health disparities, including dis-
parities in influenza vaccination coverage, is an overarching 
national goal that is not being met (334). Estimated vaccination 
coverage levels in 2007 among persons aged >65 years were 
70% for non-Hispanic whites, 58% for non-Hispanic blacks, 
and 54% for Hispanics (345). Among Medicare beneficiaries, 
other key factors that contribute to disparities in coverage 
include variations in the propensity of patients to actively 
seek vaccination and variations in the likelihood that provid-
ers recommend vaccination (346,347). One study estimated 
that eliminating these disparities in vaccination coverage would 
have an impact on mortality similar to the impact of eliminat-
ing deaths attributable to kidney disease among blacks or liver 
disease among Hispanics (348).
Reported vaccination levels are low among children at 
increased risk for influenza complications. Coverage among 
children aged 2–17 years with asthma for the 2004–05 influ-
enza season was estimated to be 29% (349). One study reported 
79% vaccination coverage among children attending a cystic 
fibrosis treatment center (350). During the first season for 
which ACIP recommended that all children aged 6 months–23 
months receive vaccination, 33% received 1 or more doses 
of influenza vaccine, and 18% received 2 doses if they were 
unvaccinated previously (351). Among children enrolled in 
HMOs who had received a first dose during 2001–2004, sec-
ond dose coverage varied from 29% to 44% among children 
aged 6–23 months and from 12% to 24% among children 
aged 2–8 years (352). A rapid analysis of influenza vaccina-
tion coverage levels among members of an HMO in Northern 
California demonstrated that during the 2004–05 influenza 
season, the first year of the recommendation for vaccination of 
children aged 6–23 months, 1-dose coverage was 57% (353). 
During the 2006–07 influenza season, the second season for 
which ACIP recommended that all children aged 6 months–23 
months receive vaccination, coverage remained low and did not 
increase substantially from the 2004–05 season. Data collected 
in 2007 by the National Immunization Survey indicated that 
for the 2006–07 season, 32% of children aged 6–23 months 
received at least 1 dose of influenza vaccine and 21% were fully 
vaccinated (i.e., received 1 or 2 doses depending on previous 
vaccination history); however, results varied substantially 
among states (354). As has been reported for older adults, a 
physician recommendation for vaccination and the percep-
tion that having a child be vaccinated “is a smart idea” were 
associated positively with likelihood of vaccination of children 
aged 6–23 months (355). Similarly, children with asthma were 
more likely to be vaccinated if their parents recalled a physician 
recommendation to be vaccinated or believed that the vaccine 
worked well (356). Implementation of a reminder/recall system 
in a pediatric clinic increased the percentage of children with 
asthma receiving vaccination from 5% to 32% (357).
Although annual vaccination is recommended for HCP 
and is a high priority for reducing morbidity associated with 
influenza in health-care settings and for expanding influenza 
vaccine use (358–360), national survey data demonstrated a 
vaccination coverage level of only 42% among HCP during the 
2005–06 season, and 44% during the 2006–07 season (Table 
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TABLE 3. Influenza vaccination* coverage levels for the 2005–06, 2006–07, and 2007-08 influenza seasons, by population group 
— National Health Interview Survey (NHIS),  United States, 2006, 2007, and 2008, and National Immunization Survey (NIS), 2006 
and 2007





Influenza vaccination level Crude 
sample 
size




% (CI§) % (CI) % (CI)
Persons with an age 
indication
Aged 6–23 mos (NIS¶) 13,546 32.2 (30.9–33.5) 9,710 31.8 (30.2–33.4) NA**
Aged 2–4 yrs 611 26.4 (22.2–31.0) 636 39.2 (34.9–43.6) 674 40.3 (35.8–45.0)
Aged 50–64 yrs 2,843 31.6 (29.5–33.8) 2,787 37.1 (34.8–39.5) 3,258 38.4 (36.4–40.4)
Aged ≥65 yrs 2,328 64.5 (62.6–66.8) 2,260 66.0 (63.7–68.3) 2,658 66.3 (64.2–68.3)
Persons with high-risk 
conditions†† 
Aged 5–17 yrs 376 22.1 (17.1–28.2) 283 28.0 (20.0–37.1) 262 36.2 (29.3–43.6)
Aged 18–49 yrs 937 23.4 (20.2–26.9) 883 25.3 (21.8–29.3) 1,049 30.4 (27.1–34.0)
Aged 50–64 yrs 878 44.3 (40.2–48.5) 824 47.8 (43.4–52.1) 1,001 48.4 (44.7–52.2)
Aged 18–64 yrs 1,815 33.4 (30.5–36.5) 2,303 35.8 (33.0–38.8) 2,050 38.8 (36.2–41.4)
Persons without high-risk 
conditions 
Aged 5–17 yrs 2,679 12.4 (10.9–14.1) 2,570 17.3 (15.4–19.2) 2,925 21.1 (19.3–23.1)
Aged 18–49 yrs 6,275 13.4 (12.4–14.6) 5.844 15.3 (14.2–16.6) 6,467 17.0 (15.7–18.3)
Aged 50–64 yrs 1,956 26.0 (23.7–28.4) 1,956 32.7 (30.3–35.2) 2,248 34.1 (31.7–36.6)
Pregnant women§§ 126 12.3 (7.2–20.4) 123 14.7 (8.9–23.2) 113 24.2 (15.1–36.6)
Health-care workers¶¶ 833 41.8 (37.4–46.3) 850 44.4 (40.2–48.7) NA
Household contacts of per-
sons at high risk, including 
children aged <5 yrs***
Aged 5–17 yrs 840 16.3 (13.4–19.7) 741 26.0 (21.5–31.1) 968 24.8 (21.4–28.6)
Aged 18–49 yrs 1621 14.4 (12.5–16.5) 1,349 17.0  (15.0–19.4) 1,753 19.5 (17.1–22.1)
 * Answered yes to this question, “During the past 12 months, have you had a flu shot (flu spray),” and answered the follow-up question “What was the 
month and year of  your most recent shot (spray).” Questions were asked during a face-to-face interview conducted any day during March through 
August in the respective study year.
 † The population sizes by subgroups is available at http://www.cdc.gov/flu/professionals/vaccination/pdf/influenza_vaccine_target_populations.pdf.
 § 95% confidence interval.
 ¶ NIS uses provider-verified vaccination status to improve the accuracy of the estimate. The NIS estimate for the 2007–08 season will be available fall 
2009 The NHIS coverage estimates based on parental report were 39.5% (CI = 32.8–46.7, n = 295) for the 2005–06 season, 48.0% (CI = 40.2–55.9; 
n = 368) for the 2006–07 season, and 49.1% (CI = 41.9–56.4) for the 2007–08 season.
 ** Data not yet available.
 †† Adults categorized as being at high risk for influenza-related complications self-reported one or more of the following: 1) ever being told by a physician 
they had diabetes, emphysema, coronary heart disease, angina, heart attack, or other heart condition; 2) having a diagnosis of cancer during the 
previous 12 months (excluding nonmelanoma skin cancer) or ever being told by a physician they have lymphoma, leukemia, or blood cancer during 
the previous 12 months (post coding for a cancer diagnosis was not yet completed at the time of this publication so this diagnosis was not include 
in the 2006–07 season data.); 3) being told by a physician they have chronic bronchitis or weak or failing kidneys; or 4) reporting an asthma episode 
or attack during the preceding 12 months. For children aged <18 years, high-risk conditions included ever having been told by a physician of having 
diabetes, cystic fibrosis, sickle cell anemia, congenital heart disease, other heart disease, or neuromuscular conditions (seizures, cerebral palsy, and 
muscular dystrophy), or having an asthma episode or attack during the preceding 12 months. 
 §§ Aged 18–44 years, pregnant at the time of the survey and without high-risk conditions.
 ¶¶ Adults were classified as health-care workers if they were employed in a health-care occupation or in a health-care–industry setting, on the basis of 
standard occupation and industry categories recoded in groups by CDC’s National Center for Health Statistics.
 *** Interviewed sample child or adult in each household containing at least one of the following: a child aged <5 years, an adult aged ≥65 years, or any 
person aged 5–17 years at high risk (see previous footnote ††). To obtain information on household composition and high-risk status of household 
members, the sampled adult, child, and person files from NHIS were merged. Interviewed adults who were health-care workers or who had high-risk 
conditions were excluded. Information could not be assessed regarding high-risk status of other adults aged 18–64 years in the household; therefore, 
certain adults aged 18–64 years who lived with an adult aged 18–64 years at high risk were not included in the analysis. Also note that although 
the recommendation for children aged 2–4 years was not in place during the 2005–06 season, children aged 2–4 years in these calculations were 
considered to have an indication for vaccination to facilitate comparison of coverage data for subsequent years.
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3). Vaccination of HCP has been associated with reduced work 
absenteeism (300) and with fewer deaths among nursing home 
patients (305,307) and elderly hospitalized patients (308). 
Factors associated with a higher rate of influenza vaccination 
among HCP include older age, being a hospital employee, 
having employer-provided health-care insurance, having had 
pneumococcal or hepatitis B vaccination in the past, or having 
visited a health-care professional during the preceding year. 
Non-Hispanic black HCP were less likely than non-Hispanic 
white HCP to be vaccinated (361). HCP who decline vacci-
nation frequently express doubts about the risk for influenza 
and the need for vaccination, are concerned about vaccine 
effectiveness and side effects, and dislike injections (362).
Vaccine coverage among pregnant women increased dur-
ing the 2007–08 influenza season with 24% of pregnant 
women reporting vaccination, excluding pregnant women 
who reported diabetes, heart disease, lung disease, and other 
selected high-risk conditions (Table 3). However, the sample 
size is small, and the increase in coverage compared with 
previous seasons was not statistically significant. In a study 
of influenza vaccine acceptance by pregnant women, 71% 
of those who were offered the vaccine chose to be vaccinated 
(363). However, a 1999 survey of obstetricians and gynecolo-
gists determined that only 39% administered influenza vaccine 
to obstetric patients in their practices, although 86% agreed 
that pregnant women’s risk for influenza-related morbidity and 
mortality increases during the last two trimesters (364).
Influenza vaccination coverage in all groups recommended 
for vaccination remains suboptimal. Despite the timing of the 
peak of influenza disease, administration of vaccine decreases 
substantially after November. According to results from the 
NHIS regarding the two most recent influenza seasons for 
which these data are available, approximately 84% of all 
influenza vaccination were administered during September–
November. Among persons aged >65 years, the percentage of 
September–November vaccinations was 92% (365). Because 
many persons recommended for vaccination remain unvacci-
nated at the end of November, CDC encourages public health 
partners and health-care providers to conduct vaccination 
clinics and other activities that promote seasonal influenza 
vaccination annually during National Influenza Vaccination 
Week (December 6–12, 2009) and throughout the remainder 
of the influenza season.
Self-report of influenza vaccination among adults compared 
with determining vaccination status from the medical record, 
is a sensitive and specific source of information (366,367). 
Patient self-reports should be accepted as evidence of influenza 
vaccination in clinical practice (367). However, information 
on the validity of parents’ reports of pediatric influenza vac-
cination is not yet available.
Recommendations for Using tIV 
and LAIV During the 2009–10 
Influenza Season
Both TIV and LAIV prepared for the 2009–10 sea-
son will include A/Brisbane/59/2007 (H1N1)-like, A/
Brisbane/10/2007 (H3N2)-like, and B/Brisbane/60/2008-like 
antigens. The influenza B virus component of the 2009–10 
vaccine is from the Victoria lineage (368). These viruses will 
be used because they are representative of seasonal influenza 
viruses that are predicted to be circulating in the United States 
during the 2009–10 influenza season and have favorable 
growth properties in eggs. Seasonal influenza vaccines are not 
expected to provide substantial protection against infection 
with the recently identified novel influenza A (H1N1) (318), 
and guidance for the prevention of infection against this virus 
will be published separately.
TIV and LAIV can be used to reduce the risk for influenza 
virus infection and its complications. Vaccination providers 
should administer influenza vaccine to any person who wishes 
to reduce the likelihood of becoming ill with influenza or trans-
mitting influenza to others should they become infected.
Healthy, nonpregnant persons aged 2–49 years can choose 
to receive either vaccine. Some TIV formulations are FDA-
licensed for use in persons as young as age 6 months (see 
Recommended Vaccines for Different Age Groups). TIV is 
licensed for use in persons with high-risk conditions (Table 
2). LAIV is FDA-licensed for use only for persons aged 2–49 
years. In addition, FDA has indicated that the safety of LAIV 
has not been established in persons with underlying medical 
conditions that confer a higher risk for influenza complica-
tions. All children aged 6 months–8 years who have not been 
vaccinated previously at any time with at least 1 dose of either 
LAIV (if appropriate) or TIV should receive 2 doses of age-
appropriate vaccine in the same season, with a single dose 
during subsequent seasons.
target Groups for Protection through 
Vaccination
Influenza vaccine should be provided to all persons who 
want to reduce the risk for becoming ill with influenza or of 
transmitting it to others. However, emphasis on providing 
routine vaccination annually to certain groups at higher risk 
for influenza infection or complications is advised, including 
all children aged 6 months–18 years, all persons aged >50 
years, and other adults at risk for medical complications from 
influenza. In addition, all persons who live with or care for per-
sons at high risk for influenza-related complications, including 
contacts of children aged <6 months, should receive influenza 
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vaccine annually (Boxes 1 and 2). Approximately 85% of the 
U.S. population is included in one or more of these target 
groups; however, <40% of the U.S. population received an 
influenza vaccination during the 2008–09 influenza season.
Children Aged 6 Months–18 Years
Beginning with the 2008–09 influenza season, annual vac-
cination for all children aged 6 months–18 years was recom-
mended. Children and adolescents at high risk for influenza 
complications should continue to be a focus of vaccination 
efforts as providers and programs transition to routinely vac-
cinating all children.
Healthy children aged 2–18 years can receive either LAIV 
or TIV. Children aged 6–23 months, and those aged 2–4 
years who have evidence of asthma wheezing or who have 
medical conditions that put them at higher risk for influenza 
complications should receive TIV (see Considerations When 
Using LAIV). All children aged 6 months–8 years who have 
not received vaccination against influenza previously should 
receive 2 doses of vaccine the first year they are vaccinated.
Persons at Risk for Medical Complications
Vaccination to prevent influenza is particularly important 
for the following persons, who are at increased risk for severe 
complications from influenza, or at higher risk for influenza-
related outpatient, ED, or hospital visits:
all children aged 6 months–4 years (59 months); •
all persons aged  • >50 years;
children and adolescents (aged 6 months–18 years) who  •
are receiving long-term aspirin therapy and who might 
be at risk for experiencing Reye syndrome after influ-
enza virus infection;
women who will be pregnant during the influenza  •
season;
adults and children who have chronic pulmonary  •
(including asthma) or cardiovascular (except hyper-
tension), renal, hepatic, neurological/neuromuscular, 
hematologic, or metabolic disorders (including diabetes 
mellitus);
adults and children who have immunosuppression  •
(including immunosuppression caused by medications 
or by HIV); and
residents of nursing homes and other long-term–care  •
facilities.
For children, the risk for severe complications from seasonal 
influenza is highest among those aged <2 years, who have much 
higher rates of hospitalization for influenza-related complica-
tions compared with older children (7,32,39). Medical care 
and ED visits attributable to influenza are increased among 
children aged <5 years compared with older children (32). 
Chronic neurologic and neuromuscular conditions include 
any condition (e.g., cognitive dysfunction, spinal cord injuries, 
seizure disorders, or other neuromuscular disorders) that can 
compromise respiratory function or the handling of respiratory 
secretions or that can increase the risk for aspiration (30).
Persons Who Live With or Care for 
Persons at High Risk for Influenza-Related 
Complications
To prevent transmission to persons identified above, vac-
cination with TIV or LAIV (unless contraindicated) also is 
recommended for the following persons. When vaccine sup-
ply is limited, vaccination efforts should focus on delivering 
vaccination to these persons:
HCP; •
household contacts (including children) and caregivers  •
of children aged <59 months (i.e., aged <5 years) and 
adults aged >50 years; and
household contacts (including children) and caregivers  •
of persons with medical conditions that put them at 
higher risk for severe complications from influenza. 
Children Aged <6 Months
Children aged <6 months are not recommended for vacci-
nation, and antivirals are not licensed for use among infants. 
Protection of young infants, who have hospitalization rates 
similar to those observed among the elderly, depends on vac-
cination of the infants’ close contacts. A recent study conducted 
in Bangladesh demonstrated that infants born to vaccinated 
women have significant protection from laboratory-confirmed 
influenza, either through transfer of influenza-specific maternal 
antibodies or by reducing the risk for exposure to influenza 
that might occur through vaccination of the mother (154). All 
household contacts, health-care and day care providers, and 
other close contacts of young infants should be vaccinated.
Vaccination of Specific Populations
Children Aged 6 Months–18 Years
All children aged 6 months–18 years should be vaccinated 
against influenza annually. In 2004, ACIP recommended 
routine vaccination for all children aged 6–23 months, and 
in 2006, ACIP expanded the recommendation to include all 
children aged 24–59 months. Recommendations to provide 
routine influenza vaccination to all children and adolescents 
aged 6 months–18 years are made on the basis of 1) accumu-
lated evidence that influenza vaccine is effective and safe for 
children (see Influenza Vaccine Efficacy, Effectiveness, and 
Safety); 2) increased evidence that influenza has substantial 
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adverse impacts among children and their contacts (e.g., school 
absenteeism, increased antibiotic use, medical care visits, and 
parental work loss) (see Health-Care Use, Hospitalizations, 
and Deaths Attributed to Influenza); and 3) an expectation 
that a simplified age-based influenza vaccine recommendation 
for all children and adolescents will improve vaccine coverage 
levels among children who already have a risk- or contact-based 
indication for annual influenza vaccination.
Children typically have the highest attack rates during com-
munity outbreaks of influenza and serve as a major source 
of transmission within communities (1,2). If sufficient vac-
cination coverage among children can be achieved, potential 
benefits include the indirect effect of reducing influenza among 
persons who have close contact with children and reducing 
overall transmission within communities. Achieving and sus-
taining community-level reductions in influenza will require 
mobilization of community resources and development of 
sustainable annual vaccination campaigns to assist health-care 
providers and vaccination programs in providing influenza 
vaccination services to children of all ages. In many areas, 
innovative community-based efforts, which might include mass 
vaccination programs in school or other community settings, 
will be needed to supplement vaccination services provided in 
health-care providers’ offices or public health clinics. In non-
randomized community-based controlled trials, reductions 
in ILI-related symptoms and medical visits among household 
contacts have been demonstrated in communities where vacci-
nation programs among school-aged children were established 
compared with communities without such vaccination pro-
grams (295,314,315).Reducing influenza-related illness among 
children who are at high risk for influenza complications should 
continue to be a primary focus of influenza-prevention efforts. 
Children who should be vaccinated because they are at high 
risk for influenza complications include all children aged 6–59 
months, children with certain medical conditions, children 
who are contacts of children aged <5 years (60 months) or 
of persons aged >50 years, and children who are contacts of 
persons at high risk for influenza complications because of 
medical conditions.
All children aged 6 months–8 years who have not received 
vaccination against influenza previously should receive 2 doses 
of vaccine the first influenza season that they are vaccinated. 
The second dose should be administered 4 or more weeks after 
the initial dose. When only 1 dose is administered to children 
aged 6 months–8 years during their first year of vaccination, 2 
doses should be administered in the following season. However, 
2 doses should only be administered in the first season of vac-
cination, or in the season that immediately follows if only 1 
dose is administered in the first season. For example, children 
aged 6 months–8 years who were vaccinated for the first time 
with the 2008–09 influenza vaccine but received only 1 dose 
should receive 2 doses of the 2009–10 influenza vaccine. All 
other children aged 6 months–8 years who have previously 
received 1 or more doses of influenza vaccine at any time should 
receive 1 dose of the 2009–10 influenza vaccine. Children 
aged 6 months–8 years who received only a single vaccination 
during a season before 2007–08 should receive 1 dose of the 
2009–10 influenza vaccine. If possible, both doses should be 
administered before onset of influenza season. However, vac-
cination, including the second dose, is recommended even after 
influenza virus begins to circulate in a community.
HCP and other Persons Who Can 
transmit Influenza to those  
at High Risk
Healthy persons who are infected with influenza virus, 
including those with subclinical infection, can transmit 
influenza virus to persons at higher risk for complications 
from influenza. In addition to HCP, groups that can transmit 
influenza to high-risk persons and that should be vaccinated 
include
employees of assisted living and other residences for  •
persons in groups at high risk;
persons who provide home care to persons in groups at  •
high risk; and
household contacts of persons in groups at high risk,  •
including contacts such as children or mothers of 
newborns.
In addition, because children aged <5 years are at increased 
risk for influenza-related hospitalization (7,31,39,369,370) 
compared with older children, vaccination is recommended for 
their household contacts and out-of-home caregivers. Because 
influenza vaccines have not been licensed by FDA for use 
among children aged <6 months, emphasis should be placed 
on vaccinating contacts of these children.
Healthy HCP and persons aged 2–49 years who are con-
tacts of persons in these groups and who are not contacts of 
severely immunosuppressed persons (see Close Contacts of 
Immunocompromised Persons) should receive either LAIV or 
TIV when indicated or requested. All other persons, including 
pregnant women, should receive TIV.
All HCP and persons in training for health-care professions 
should be vaccinated annually against influenza. Persons work-
ing in health-care settings who should be vaccinated include 
physicians, nurses, and other workers in both hospital and 
outpatient-care settings, medical emergency-response workers 
(e.g., paramedics and emergency medical technicians), employ-
ees of nursing home and long-term–care facilities who have 
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contact with patients or residents, and students in these profes-
sions who will have contact with patients (359,360,371).
Facilities that employ HCP should provide vaccine to 
workers by using approaches that have been demonstrated to 
be effective in increasing vaccination coverage. Health-care 
administrators should consider the level of vaccination cover-
age among HCP to be one measure of a patient safety quality 
program and consider obtaining signed declinations from 
personnel who decline influenza vaccination for reasons other 
than medical contraindications (360,372,373). Influenza vac-
cination rates among HCP within facilities should be regularly 
measured and reported, and ward-, unit-, and specialty-specific 
coverage rates should be provided to staff and administration 
(360). Studies have demonstrated that organized campaigns 
can attain higher rates of vaccination among HCP with 
moderate effort and by using strategies that increase vaccine 
acceptance (358,360,374).
Efforts to increase vaccination coverage among HCP are 
supported by various national accrediting and professional 
organizations and in certain states by statute. The Joint 
Commission on Accreditation of Health-Care Organizations 
has approved an infection-control standard that requires 
accredited organizations to offer influenza vaccinations to staff, 
including volunteers and licensed independent practitioners 
with close patient contact. The standard became an accredita-
tion requirement beginning January 1, 2007 (375). In addition, 
the Infectious Diseases Society of America has recommended 
mandatory vaccination for HCP, with a provision for declina-
tion of vaccination based on religious or medical reasons (376). 
Some states have regulations regarding vaccination of HCP in 
long-term–care facilities (377), require that health-care facilities 
offer influenza vaccination to HCP, or require that HCP either 
receive influenza vaccination or indicate a religious, medical, 
or philosophic reason for not being vaccinated (378,379).
Close Contacts of 
Immunocompromised Persons
Immunocompromised persons are at risk for influenza 
complications but might have inadequate protection after 
vaccination. Close contacts of immunocompromised persons, 
including HCP, should be vaccinated to reduce the risk for 
influenza transmission. TIV is recommended for vaccinating 
household members, HCP, and others who have close contact 
with severely immunosuppressed persons (e.g., patients with 
hematopoietic stem cell transplants) during those periods 
in which the immunosuppressed person requires care in a 
protective environment (typically defined as a specialized 
patient-care area with a positive airflow relative to the cor-
ridor, high-efficiency particulate air filtration, and frequent 
air changes) (360,380).
LAIV transmission from a recently vaccinated person caus-
ing clinically important illness in an immunocompromised 
contact has not been reported. The rationale for avoiding 
use of LAIV among HCP or other close contacts of severely 
immunocompromised patients is the theoretical risk that a live, 
attenuated vaccine virus could be transmitted to the severely 
immunosuppressed person. As a precautionary measure, HCP 
who receive LAIV should avoid providing care for severely 
immunosuppressed patients requiring a protected environment 
for 7 days after vaccination. Hospital visitors who have received 
LAIV should avoid contact with severely immunosuppressed 
persons in protected environments for 7 days after vaccina-
tion but should not be restricted from visiting less severely 
immunosuppressed patients.
No preference is indicated for TIV use by persons who have 
close contact with persons with lesser degrees of immunosup-
pression (e.g., persons with diabetes, persons with asthma 
who take corticosteroids, persons who have recently received 
chemotherapy or radiation but who are not being cared for in 
a protective environment as defined above, or persons infected 
with HIV) or for TIV use by HCP or other healthy nonpreg-
nant persons aged 2–49 years in close contact with persons in 
all other groups at high risk.
Pregnant Women
Pregnant women and newborns are at risk for influenza 
complications, and all women who are pregnant or will 
be pregnant during influenza season should be vaccinated. 
The American College of Obstetricians and Gynecologists 
and the American Academy of Family Physicians also have 
recommended routine vaccination of all pregnant women 
(381). No preference is indicated for use of TIV that does not 
contain thimerosal as a preservative (see Vaccine Preservative 
[Thimerosal] in Multidose Vials of TIV) for any group recom-
mended for vaccination, including pregnant women. LAIV is 
not licensed for use in pregnant women. However, pregnant 
women do not need to avoid contact with persons recently 
vaccinated with LAIV.
Breastfeeding Mothers
Vaccination is recommended for all persons, including 
breastfeeding women, who are contacts of infants or children 
aged <5 years because infants and young children are at high 
risk for influenza complications and are more likely to require 
medical care or hospitalization if infected. Breastfeeding does 
not affect the immune response adversely and is not a con-
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traindication for vaccination (179). Unless contraindicated 
because of other medical conditions, women who are breast-
feeding can receive either TIV or LAIV. In one randomized 
controlled trial conducted in Bangladesh, infants born to 
women vaccinated during pregnancy had a lower risk for 
laboratory-confirmed influenza. However, the contribution 
to protection from influenza of breastfeeding compared with 
passive transfer of maternal antibodies during pregnancy was 
not determined (154).
travelers
The risk for exposure to influenza during travel depends on 
the time of year and destination. In the temperate regions of 
the Southern Hemisphere, influenza activity occurs typically 
during April–September. In temperate climate zones of the 
Northern and Southern Hemispheres, travelers also can be 
exposed to influenza during the summer, especially when 
traveling as part of large tourist groups (e.g., on cruise ships) 
that include persons from areas of the world in which influ-
enza viruses are circulating (382,383). In the tropics, influenza 
occurs throughout the year. In a study among Swiss travelers 
to tropical and subtropical countries, influenza was the most 
frequently acquired vaccine-preventable disease (384).
Any traveler who wants to reduce the risk for influenza infec-
tion should consider influenza vaccination, preferably at least 
2 weeks before departure. In particular, persons at high risk 
for complications of influenza and who were not vaccinated 
with influenza vaccine during the preceding fall or winter 
should consider receiving influenza vaccine before travel if 
they plan to travel
to the tropics, •
with organized tourist groups at any time of year, or •
to the Southern Hemisphere during April–September. •
No information is available about the benefits of revac-
cinating persons before summer travel who already were 
vaccinated during the preceding fall, and revaccination is not 
recommended. Persons at high risk who receive the previous 
season’s vaccine before travel should be revaccinated with the 
current vaccine the following fall or winter. Persons at higher 
risk for influenza complications should consult with their 
health-care practitioner to discuss the risk for influenza or 
other travel-related diseases before embarking on travel dur-
ing the summer.
General Population
Vaccination is recommended for any persons who wish to 
reduce the likelihood of their becoming ill with influenza or 
transmitting influenza to others should they become infected. 
Healthy, nonpregnant persons aged 2–49 years might choose to 
receive either TIV or LAIV. All other persons aged >6 months 
should receive TIV. Persons who provide essential community 
services should be considered for vaccination to minimize 
disruption of essential activities during influenza outbreaks. 
Students or other persons in institutional settings (e.g., those 
who reside in dormitories or correctional facilities) should be 
encouraged to receive vaccine to minimize morbidity and the 
disruption of routine activities during influenza epidemics 
(385,386).
Recommended Vaccines for Different 
Age Groups
When vaccinating children aged 6–35 months with TIV, 
health-care providers should use TIV that has been licensed 
by the FDA for this age group (i.e., TIV manufactured by 
Sanofi Pasteur [FluZone]) (219). TIV from Novartis (Fluvirin) 
is FDA-approved in the United States for use among persons 
aged >4 years (220). TIV from GlaxoSmithKline (Fluarix and 
FluLaval) or CSL Biotherapies (Afluria) is labeled for use in 
persons aged >18 years because data to demonstrate immu-
nogenicity or efficacy among younger persons have not been 
provided to FDA (207,208,218). LAIV from MedImmune 
(FluMist) is recommended for use by healthy nonpregnant 
persons aged 2–49 years (Table 2) (291). If a pediatric vac-
cine dose (0.25mL) is administered to an adult, an additional 
pediatric dose (0.25 mL) should be given to provide a full 
adult dose (0.5mL). If the error is discovered later (after the 
patient has left the vaccination setting), an adult dose should be 
administered as soon as the patient can return. No action needs 
to be taken if an adult dose is administered to a child. Several 
new vaccine formulations are being evaluated in immunogenic-
ity and efficacy trials; when licensed, these new products will 
increase the influenza vaccine supply and provide additional 
vaccine choices for practitioners and their patients.
Influenza Vaccines and Use  
of Influenza Antiviral Medications
Unvaccinated persons who are receiving antiviral medications 
for treatment or chemoprophylaxis often also are recommended 
for vaccination. Administration of TIV to persons receiving 
influenza antivirals is acceptable. The effect on safety and 
effectiveness of LAIV coadministration with influenza antiviral 
medications has not been studied. However, because influenza 
antivirals reduce replication of influenza viruses, LAIV should 
not be administered until 48 hours after cessation of influenza 
antiviral therapy, and influenza antiviral medications should 
not be administered for 2 weeks after receipt of LAIV. Persons 
receiving antivirals within the period 2 days before to 14 days 
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after vaccination with LAIV should be revaccinated at a later 
date with any approved vaccine formulation (179,291).
Considerations When Using LAIV
LAIV is an option for vaccination of healthy, nonpregnant 
persons aged 2–49 years, including HCP and other close 
contacts of high-risk persons (excepting severely immuno-
compromised persons who require care in a protected envi-
ronment). No preference is indicated for LAIV or TIV when 
considering vaccination of healthy,¶ nonpregnant persons aged 
2–49 years. Possible advantages of LAIV include its potential 
to induce a broad mucosal and systemic immune response in 
children, its ease of administration, and the possibly increased 
acceptability of an intranasal rather than intramuscular route 
of administration.
If the vaccine recipient sneezes after administration, the dose 
should not be repeated. However, if nasal congestion is present 
that might impede delivery of the vaccine to the nasopharyn-
geal mucosa, deferral of administration should be considered 
until resolution of the illness, or TIV should be administered 
instead. No data exist about concomitant use of nasal corti-
costeroids or other intranasal medications (261).
Although FDA licensure of LAIV excludes children aged 
2–4 years with a history of asthma or recurrent wheezing, the 
precise risk, if any, of wheezing caused by LAIV among these 
children is unknown because experience with LAIV among 
these young children is limited. Young children might not have 
a history of recurrent wheezing if their exposure to respiratory 
viruses has been limited because of their age. Certain children 
might have a history of wheezing with respiratory illnesses but 
have not had asthma diagnosed.
The following screening recommendations should be used to 
assist persons who administer influenza vaccines in providing 
the appropriate vaccine for children aged 2–4 years.
Clinicians and vaccination programs should screen  •
for asthma or wheezing illness (or history of wheez-
ing illness) when considering use of LAIV for children 
aged 2–4 years, and should avoid use of this vaccine 
in children with asthma or a recent wheezing episode 
within the previous 12 months. Health-care providers 
should consult the medical record, when available, to 
identify children aged 2–4 years with asthma or recur-
rent wheezing that might indicate asthma. In addition, 
to identify children who might be at greater risk for 
asthma and possibly at increased risk for wheezing after 
receiving LAIV, parents or caregivers of children aged 
2–4 years should be asked: “In the past 12 months, 
has a health-care provider ever told you that your child 
had wheezing or asthma?” Children whose parents or 
caregivers answer “yes” to this question and children 
who have asthma or who had a wheezing episode noted 
in the medical record during the preceding 12 months 
should not receive LAIV. TIV is available for use in 
children with asthma or wheezing (387).LAIV can 
be administered to persons with minor acute illnesses 
(e.g., diarrhea or mild upper respiratory tract infection 
with or without fever). However, if nasal congestion is 
present that might impede delivery of the vaccine to 
the nasopharyngeal mucosa, deferral of administration 
should be considered until resolution of the illness.
Contraindications and Precautions for 
Use of LAIV
The effectiveness or safety of LAIV is not known for 
the following groups and administration of LAIV is 
contraindicated:
persons with a history of hypersensitivity, including ana- •
phylaxis, to any of the components of LAIV or to eggs.
persons aged <2 years or those aged  • >50 years;
adults and children who have chronic pulmonary  •
(including asthma), cardiovascular (except hyperten-
sion), renal, hepatic, neurological/neuromuscular, hema-
tological, or metabolic disorders (including diabetes 
mellitus);
adults and children who have immunosuppression  •
(including immunosuppression caused by medications 
or by HIV);
children aged 2–4 years whose parents or caregivers  •
report that a health-care provider has told them during 
the preceding 12 months that their child had wheez-
ing or asthma, or whose medical record indicates a 
wheezing episode has occurred during the preceding 12 
months;
children or adolescents aged 6 months–18 years receiv- •
ing aspirin or other salicylates (because of the associa-
tion of Reye syndrome with wild-type influenza virus 
infection); or
pregnant women. •
A moderate or severe illness with or without fever is a precau-
tion for use of LAIV. GBS within 6 weeks following a previous 
dose of influenza vaccine is considered to be a precaution for 
use of influenza vaccines. LAIV should not be administered 
to close contacts of immunosuppressed persons who require 
a protected environment.¶
 Use of the term “healthy” in this recommendation refers to persons who do not 
have any of the underlying medical conditions that confer high risk for severe 
complications (see Contraindications and Precautions for Use of LAIV).
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Personnel Who Can Administer LAIV
Low-level introduction of vaccine viruses into the environ-
ment probably is unavoidable when administering LAIV. The 
risk for acquiring vaccine viruses from the environment is 
unknown but is probably low. Severely immunosuppressed 
persons should not administer LAIV. However, other persons 
at higher risk for influenza complications can administer LAIV. 
These include persons with underlying medical conditions 
placing them at higher risk or who are likely to be at risk, 
including pregnant women, persons with asthma, and persons 
aged >50 years.
Concurrent Administration of 
Influenza Vaccine with other Vaccines
Use of LAIV concurrently with measles, mumps, rubella 
(MMR) alone and MMR and varicella vaccine among children 
aged 12–15 months has been studied, and no interference with 
the immunogenicity to antigens in any of the vaccines was 
observed (261,388). Among adults aged >50 years, the safety 
and immunogenicity of zoster vaccine and TIV was similar 
whether administered simultaneously or spaced 4 weeks apart 
(389). In the absence of specific data indicating interference, 
following ACIP’s general recommendations for vaccination 
is prudent (179). Inactivated vaccines do not interfere with 
the immune response to other inactivated vaccines or to live 
vaccines. Inactivated or live vaccines can be administered 
simultaneously with LAIV. However, after administration of 
a live vaccine, at least 4 weeks should pass before another live 
vaccine is administered.
Recommendations for Vaccination 
Administration and Vaccination 
Programs
Although influenza vaccination levels increased substan-
tially during the 1990s, little progress has been made since 
2000 toward achieving national health objectives, and further 
improvements in vaccine coverage levels are needed to reduce 
the annual impact of influenza substantially. Strategies to 
improve vaccination levels, including using reminder/recall 
systems and standing orders programs (335,336,345), should 
be implemented whenever feasible. Vaccination efforts should 
begin as soon as vaccine is available and continue through the 
influenza season. Vaccination coverage can be increased by 
administering vaccine before and during the influenza season 
to persons during hospitalizations or routine health-care vis-
its. Vaccinations can be provided in alternative settings (e.g., 
pharmacies, grocery stores, workplaces, or other locations in 
the community), thereby making special visits to physicians’ 
offices or clinics unnecessary. Coordinated campaigns such as 
the National Influenza Vaccination Week (December 6–12, 
2009) provide opportunities to refocus public attention on 
the benefits, safety, and availability of influenza vaccination 
throughout the influenza season. When educating patients 
about adverse events, clinicians should provide access to 
Vaccine Information Sheets (available at http://www.cdc.
gov/vaccines/pubs/vis), and emphasize that 1) TIV contains 
noninfectious killed viruses and cannot cause influenza, 2) 
LAIV contains weakened influenza viruses that cannot replicate 
outside the upper respiratory tract and are unlikely to infect 
others, and 3) concomitant symptoms or respiratory disease 
unrelated to vaccination with either TIV or LAIV can occur 
after vaccination. Adverse events after influenza vaccination 
should be reported promptly to VAERS at http://vaers.hhs.
gov even if the health-care professional is not certain that the 
vaccine caused the event.
Information About the Vaccines for 
Children Program
The Vaccines for Children (VFC) program supplies vaccine 
to all states, territories, and the District of Columbia for use 
by participating providers. These vaccines are to be provided 
to eligible children without vaccine cost to the patient or the 
provider, although the provider might charge a vaccine admin-
istration fee. All routine childhood vaccines recommended by 
ACIP are available through this program, including influenza 
vaccines. The program saves parents and providers out-of-
pocket expenses for vaccine purchases and provides cost sav-
ings to states through CDC’s vaccine contracts. The program 
results in lower vaccine prices and ensures that all states pay 
the same contract prices. Detailed information about the VFC 
program is available at http://www.cdc.gov/vaccines/programs/
vfc/default.htm.
Influenza Vaccine Supply 
Considerations
The annual supply of influenza vaccine and the timing of 
its distribution cannot be guaranteed in any year. During the 
2008–09 influenza season, 113 million doses of influenza vac-
cine were distributed in the United States. For the 2009–10 
season, total production of seasonal influenza vaccine for 
the United States is anticipated to be >130 million doses, 
depending on demand and production yields. However, influ-
enza vaccine distribution delays or vaccine shortages remain 
possible. One factor that affects production is the inherent 
critical time constraints in manufacturing the vaccine given 
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the annual updating of the influenza vaccine strains. Multiple 
manufacturing and regulatory issues, including the anticipated 
need to produce a separate vaccine against novel influenza A 
(H1N1), also might affect the production schedule. To ensure 
optimal use of available doses of influenza vaccine, health-care 
providers, persons planning organized campaigns, and state and 
local public health agencies should develop plans for expand-
ing outreach and infrastructure to vaccinate more persons in 
targeted groups and others who wish to reduce their risk for 
influenza. They also should develop contingency plans for the 
timing and prioritization of administering influenza vaccine if 
the supply of vaccine is delayed or reduced.
If supplies of TIV are not adequate, vaccination should be 
carried out in accordance with local circumstances of supply 
and demand based on the judgment of state and local health 
officials and health-care providers. Guidance for tiered use of 
TIV during prolonged distribution delays or supply short falls 
is available at http://www.cdc.gov/flu/professionals/vaccina-
tion/vax_priority.htm and will be modified as needed in the 
event of shortage. CDC and other public health agencies will 
assess the vaccine supply on a continuing basis throughout the 
manufacturing period and will inform both providers and the 
general public if any indication exists of a substantial delay or 
an inadequate supply.
Because LAIV is recommended for use only in healthy non-
pregnant persons aged 2–49 years, no recommendations for 
prioritization of LAIV use are made. Either LAIV or TIV can 
be used when considering vaccination of healthy, nonpregnant 
persons aged 2–49 years. However, during shortages of TIV, 
LAIV should be used preferentially when feasible for all healthy 
nonpregnant persons aged 2–49 years (including HCP) who 
desire or are recommended for vaccination to increase the 
availability of inactivated vaccine for persons at high risk.
timing of Vaccination
Vaccination efforts should be structured to ensure the vacci-
nation of as many persons as possible over the course of several 
months, with emphasis on vaccinating before influenza activity 
in the community begins. Even if vaccine distribution begins 
before October, distribution probably will not be completed 
until December or January. The following recommendations 
reflect this phased distribution of vaccine.
In any given year, the optimal time to vaccinate patients can-
not be determined precisely because influenza seasons vary in 
their timing and duration, and more than one outbreak might 
occur in a single community in a single year. In the United 
States, localized outbreaks that indicate the start of seasonal 
influenza activity can occur as early as October. However, in 
>80% of influenza seasons since 1976, peak influenza activity 
(which often is close to the midpoint of influenza activity for 
the season) has not occurred until January or later, and in >60% 
of seasons, the peak was in February or later (Figure 1). In 
general, health-care providers should begin offering vaccination 
soon after vaccine becomes available and if possible by October. 
To avoid missed opportunities for vaccination, providers should 
offer vaccination during routine health-care visits or during 
hospitalizations whenever vaccine is available. The potential 
for addition of a novel influenza A (H1N1) vaccine program 
to the current burden on vaccination programs and providers 
underscores the need for careful planning of seasonal vaccina-
tion programs. Beginning use of seasonal vaccine as soon as 
available, including in September or earlier, might reduce the 
overlap of seasonal and novel influenza vaccination efforts.
Vaccination efforts should continue throughout the season, 
because the duration of the influenza season varies, and influ-
enza might not appear in certain communities until February or 
March. Providers should offer influenza vaccine routinely, and 
organized vaccination campaigns should continue throughout 
the influenza season, including after influenza activity has 
begun in the community. Vaccine administered in December 
or later, even if influenza activity has already begun, is likely to 
be beneficial in the majority of influenza seasons. The major-
ity of adults have antibody protection against influenza virus 
infection within 2 weeks after vaccination (390,391).
All children aged 6 months–8 years who have not received 
vaccination against influenza previously should receive their 
first dose as soon after vaccine becomes available as is feasible 
and should receive the second dose >4 weeks later. This practice 
increases the opportunity for both doses to be administered 
before or shortly after the onset of influenza activity.
Vaccination clinics should be scheduled through December, 
and later if feasible, with attention to settings that serve chil-
dren aged >6 months, pregnant women, other persons aged 
<50 years at increased risk for influenza-related complications, 
persons aged >50 years, HCP, and persons who are household 
contacts of children aged <59 months or other persons at 
high risk. Planners are encouraged to develop the capacity 
and flexibility to schedule at least one vaccination clinic in 
December. Guidelines for planning large-scale vaccination 
clinics are available at http://www.cdc.gov/flu/professionals/
vaccination/vax_clinic.htm.
During a vaccine shortage or delay, substantial proportions 
of TIV doses might not be released and distributed until 
November and December or later. When the vaccine is sub-
stantially delayed or disease activity has not subsided, providers 
should consider offering vaccination clinics into January and 
beyond as long as vaccine supplies are available. Campaigns 
using LAIV also can extend into January and beyond.
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Strategies for Implementing 
Vaccination Recommendations in 
Health-Care Settings
Successful vaccination programs combine publicity and 
education for HCP and other potential vaccine recipients, a 
plan for identifying persons recommended for vaccination, 
use of reminder/recall systems, assessment of practice-level 
vaccination rates with feedback to staff, and efforts to remove 
administrative and financial barriers that prevent persons 
from receiving the vaccine, including use of standing orders 
programs (336,392). The use of standing orders programs by 
long-term–care facilities (e.g., nursing homes and skilled nurs-
ing facilities), hospitals, and home health agencies ensures that 
vaccination is offered. Standing orders programs for influenza 
vaccination should be conducted under the supervision of a 
licensed practitioner according to a physician-approved facility 
or agency policy by HCP trained to screen patients for con-
traindications to vaccination, administer vaccine, and monitor 
for adverse events. The Centers for Medicare and Medicaid 
Services (CMS) has removed the physician signature require-
ment for the administration of influenza and pneumococcal 
vaccines to Medicare and Medicaid patients in hospitals, 
long-term–care facilities, and home health agencies (393). 
To the extent allowed by local and state law, these facilities 
and agencies can implement standing orders for influenza 
and pneumococcal vaccination of Medicare- and Medicaid-
eligible patients. Payment for influenza vaccine under Medicare 
Part B is available (394,395) Other settings (e.g., outpatient 
facilities, managed care organizations, assisted living facilities, 
correctional facilities, pharmacies, and adult workplaces) are 
encouraged to introduce standing orders programs (396). 
In addition, physician reminders (e.g., flagging charts) and 
patient reminders are recognized strategies for increasing rates 
of influenza vaccination. Persons for whom influenza vaccine is 
recommended can be identified and vaccinated in the settings 
described in the following sections.
outpatient Facilities Providing ongoing Care
Staff in facilities providing ongoing medical care (e.g., 
physicians’ offices, public health clinics, employee health 
clinics, hemodialysis centers, hospital specialty-care clinics, 
and outpatient rehabilitation programs) should identify and 
label the medical records of patients who should receive vac-
cination. Vaccine should be offered during visits throughout 
the influenza season. The offer of vaccination and its receipt 
or refusal should be documented in the medical record or vac-
cination information system. Patients for whom vaccination is 
recommended and who do not have regularly scheduled visits 
during the fall should be reminded by mail, telephone, or other 
means of the need for vaccination.
outpatient Facilities Providing Episodic or 
Acute Care
Acute health-care facilities (e.g., EDs and walk-in clinics) 
should offer vaccinations throughout the influenza season to 
persons for whom vaccination is recommended or provide 
written information regarding why, where, and how to obtain 
the vaccine. This written information should be available in lan-
guages appropriate for the populations served by the facility.
nursing Homes and other Long-term–Care 
Facilities
Vaccination should be provided routinely to all residents of 
long-term–care facilities. If possible, all residents should be 
vaccinated at one time before influenza season. In the major-
ity of seasons, TIV will become available to long-term–care 
facilities in October or November, and vaccination should com-
mence as soon as vaccine is available. As soon as possible after 
admission to the facility, the benefits and risks of vaccination 
should be discussed and education materials provided (397). 
Signed consent is not required (398). Residents admitted after 
completion of the vaccination program at the facility should 
be vaccinated at the time of admission.
Since October 2005, CMS has required nursing homes 
participating in the Medicare and Medicaid programs to 
offer all residents influenza and pneumococcal vaccines and 
to document the results. According to the requirements, each 
resident is to be vaccinated unless contraindicated medically, 
the resident or a legal representative refuses vaccination, or the 
vaccine is not available because of shortage. This information is 
to be reported as part of the CMS Minimum Data Set, which 
tracks nursing home health parameters (395,399).
Acute-Care Hospitals
Hospitals should serve as a key setting for identifying persons 
at increased risk for influenza complications. Unvaccinated 
persons of all ages (including children) with high-risk condi-
tions and persons aged 6 months–18 years or >50 years who 
are hospitalized at any time during the period when vaccine is 
available should be offered and strongly encouraged to receive 
influenza vaccine before they are discharged. Standing orders 
to offer influenza vaccination to all hospitalized persons should 
be considered.
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Visiting nurses and others Providing Home 
Care to Persons at High Risk
Nursing-care plans should identify patients for whom vac-
cination is recommended, and vaccine should be administered 
in the home if necessary as soon as influenza vaccine is avail-
able and throughout the influenza season. Caregivers and 
other persons in the household (including children) should 
be referred for vaccination.
other Facilities Providing Services to Persons 
Aged >50 Years
Facilities providing services to persons aged >50 years (e.g., 
assisted living housing, retirement communities, and recreation 
centers) should offer unvaccinated residents, attendees, and 
staff annual on-site vaccination before the start of the influenza 
season. Continuing to offer vaccination throughout the fall 
and winter months is appropriate. Efforts to vaccinate newly 
admitted patients or new employees also should be continued, 
both to prevent illness and to avoid having these persons serve 
as a source of new influenza infections. Staff education should 
emphasize the benefits for self, staff and patients of protection 
from influenza through vaccination.
Health-Care Personnel
Health-care facilities should offer influenza vaccinations 
to all HCP, including night, weekend, and temporary staff. 
Particular emphasis should be placed on providing vaccina-
tions to workers who provide direct care for persons at high 
risk for influenza complications. Efforts should be made to 
educate HCP regarding the benefits of vaccination and the 
potential health consequences of influenza illness for their 
patients, themselves, and their family members. All HCP 
should be provided convenient access to influenza vaccine 
at the work site, free of charge, as part of employee health 
programs (360,374,375).
Future Directions for Research 
and Recommendations Related to 
Influenza Vaccine
Although available influenza vaccines are effective and safe, 
additional research is needed to improve prevention efforts. 
Most mortality from influenza occurs among persons aged >65 
years (6), and more immunogenic influenza vaccines are needed 
for this age group and other groups at high risk for mortality. 
Additional research also is needed to understand potential 
biases in estimating the benefits of vaccination among older 
adults in reducing hospitalizations and deaths (82,175,400). 
Additional studies of the relative cost-effectiveness and cost 
utility of influenza vaccination among children and adults, 
especially those aged <65 years, are needed and should be 
designed to account for year-to-year variations in influenza 
attack rates, illness severity, hospitalization costs and rates, 
and vaccine effectiveness when evaluating the long-term costs 
and benefits of annual vaccination (401). Additional data on 
indirect effects of vaccination also are needed to quantify the 
benefits of influenza vaccination of HCP in protecting their 
patients (308) and the benefits of vaccinating children to 
reduce influenza complications among those at risk. Because 
expansions in ACIP recommendations for vaccination will 
lead to more persons being vaccinated, much larger research 
networks are needed that can identify and assess the causal-
ity of very rare events that occur after vaccination, including 
GBS. Ongoing studies of safety in pediatric populations with 
expanded recommendations are needed and are underway. 
These research networks also could provide a platform for effec-
tiveness and safety studies in the event of a pandemic. A recent 
study showed that influenza vaccines contain structures that 
can induce anti-GM1 antibodies after inoculation into mice 
(402). Further research on potential biologic or genetic risk 
factors for GBS in humans also is needed (397). In addition, 
a better understanding is needed of how to motivate persons 
at risk to seek annual influenza vaccination.
ACIP continues to review new vaccination strategies to pro-
tect against influenza, including the possibility of expanding 
routine influenza vaccination recommendations toward uni-
versal vaccination or other approaches that will help reduce or 
prevent the transmission of influenza and reduce the burden of 
severe disease (403–408). The 2009 ACIP expansion of annual 
vaccination recommendations to include all children aged 6 
months–18 years will require a substantial increase in resources 
for epidemiologic research to develop long-term studies capable 
of assessing the possible effects on community-level transmis-
sion. Additional planning to improve surveillance systems 
capable of monitoring effectiveness, safety and vaccine cover-
age, and further development of implementation strategies will 
also be necessary. In addition, as noted by the National Vaccine 
Advisory Committee, strengthening the U.S. influenza vac-
cination system will require improving vaccine financing and 
demand and implementing systems to help better understand 
the burden of influenza in the United States (409). Vaccination 
programs capable of delivering annual influenza vaccination 
to a broad range of the population could potentially serve as 
a resilient and sustainable platform for delivering vaccines 
and monitoring outcomes for other urgently required public 
health interventions (e.g., vaccines for pandemic influenza 
or medications to prevent or treat illnesses caused by acts of 
terrorism).
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Seasonal Influenza Vaccine and 
Influenza Viruses of Animal origin
Human infection with novel or nonhuman influenza A 
virus strains, including influenza A viruses of animal origin, 
is a nationally notifiable disease (410). Human infections 
with nonhuman or novel human influenza A virus should 
be identified quickly and investigated to determine possible 
sources of exposure, identify additional cases, and evaluate 
the possibility of human-to-human transmission because 
transmission patterns could change over time with variations 
in these influenza A viruses.
Sporadic severe and fatal human cases of infection with 
highly pathogenic avian influenza A (H5N1) virus have been 
identified in Asia, Africa, Europe, and the Middle East, primar-
ily among persons who have had direct or close unprotected 
contact with sick or dead birds associated with the ongoing 
H5N1 panzootic among birds (411–419). Limited, nonsus-
tained human-to-human transmission of H5N1 virus has 
likely occurred in some case clusters (420,421). To date, no 
evidence exists of genetic reassortment between human influ-
enza A and H5N1 viruses. However, influenza viruses derived 
from strains circulating among poultry (e.g., the H5N1 virus 
that has caused outbreaks of avian influenza and occasionally 
have infected humans) have the potential to recombine with 
human influenza A viruses (422,423). To date, highly patho-
genic H5N1 virus has not been identified in wild or domestic 
birds or in humans in the United States. Guidance for testing 
suspected cases of H5N1 virus infection among persons in the 
U.S. and follow-up of contacts is available (424,425).
Human illness from infection with different avian influenza 
A subtype viruses also have been documented, including infec-
tions with low pathogenic and highly pathogenic viruses. A 
range of clinical illness has been reported for human infec-
tion with low pathogenic avian influenza viruses, including 
conjunctivitis with influenza A (H7N7) virus in the United 
Kingdom, lower respiratory tract disease and conjunctivitis 
with influenza A (H7N2) virus in the United Kingdom, and 
uncomplicated ILI with influenza A (H9N2) virus in Hong 
Kong and China (426–432). Two human cases of infection 
with low pathogenic influenza A (H7N2) were reported in the 
United States (429). Although human infections with highly 
pathogenic A (H7N7) virus infections typically have ILI or 
conjunctivitis, severe infections, including one fatal case in the 
Netherlands, have been reported (433,434). Conjunctivitis 
also has been reported because of human infection with highly 
pathogenic influenza A (H7N3) virus in Canada and low 
pathogenic A (H7N3) in the United Kingdom (426,434). 
In contrast, sporadic infections with highly pathogenic avian 
influenza A (H5N1) virus have caused severe illness in many 
countries, with an overall case-fatality proportion of >60% 
(421,435).
Swine influenza A (H1N1), A (H1N2), and A (H3N2) 
viruses, including reassortant viruses, are endemic among 
pig populations in the United States (436). Two clusters of 
influenza A (H2N3) virus infections among pigs have been 
reported recently (437). Outbreaks among pigs normally occur 
in colder weather months (late fall and winter) and sometimes 
with the introduction of new pigs into susceptible herds. An 
estimated 30% of the pig population in the United States has 
serologic evidence of having had swine influenza A (H1N1) 
virus infection. Sporadic human infections with a variety of 
swine influenza A viruses occur in the United States, but the 
incidence of these human infections is unknown (438–443). 
Persons infected with swine influenza A viruses typically report 
direct contact with ill pigs or places where pigs have been 
present (e.g., agricultural fairs or farms), and have symptoms 
that are clinically indistinguishable from infection with other 
respiratory viruses (440,441,444,445). Clinicians should 
consider swine influenza A virus infection in the differential 
diagnosis of patients with ILI who have had recent contact 
with pigs. The sporadic cases identified in recent years have 
not resulted in sustained human-to-human transmission of 
swine influenza A viruses or community outbreaks (368,445). 
Although immunity to swine influenza A viruses appears to 
be low (<2%) in the overall human population, 10%–20% of 
persons exposed occupationally to pigs (e.g., pig farmers or 
pig veterinarians) have been documented in certain studies to 
have antibody evidence of prior swine influenza A (H1N1) 
virus infection (438,446).
In April 2009, a novel influenza A (H1N1) virus similar to 
influenza viruses previously identified in swine was determined 
to the cause of an influenza-like respiratory illness among 
humans that spread across North America and throughout most 
of the world by May 2009 (9,447). The epidemiology of influ-
enza caused by this novel influenza virus is still being studied, 
and whether this virus will achieve long-term circulation among 
humans or even replace one of the other seasonal influenza 
viruses as the cause of annual epidemics is unknown.
Current seasonal influenza vaccines are not expected to pro-
vide protection against human infection with avian influenza 
A viruses, including influenza A (H5N1) viruses, or to provide 
protection against currently circulating swine influenza A or 
the novel influenza A (H1N1) viruses (318,448). However, 
reducing seasonal influenza risk through influenza vaccination 
of persons who might be exposed to nonhuman influenza 
viruses (e.g., H5N1 virus) might reduce the theoretical risk 
for recombination of influenza A viruses of animal origin and 
human influenza A viruses by preventing seasonal influenza 
A virus infection within a human host.
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CDC has recommended that persons who are charged 
with responding to avian influenza outbreaks among poultry 
receive seasonal influenza vaccination (448,449). As part of 
preparedness activities, the Occupational Safety and Health 
Administration (OSHA) has issued an advisory notice regard-
ing poultry worker safety that is intended for implementation 
in the event of a suspected or confirmed avian influenza out-
break at a poultry facility in the United States. OSHA guide-
lines recommend that poultry workers in an involved facility 
receive vaccination against seasonal influenza; OSHA also 
has recommended that HCP involved in the care of patients 
with documented or suspected avian influenza should be vac-
cinated with the most recent seasonal human influenza vaccine 
to reduce the risk for co-infection with human influenza A 
viruses (449).
Recommendations for Using 
Antiviral Agents for Seasonal 
Influenza
Annual vaccination is the primary strategy for preventing 
complications of influenza virus infections. Antiviral medica-
tions with activity against influenza viruses are useful adjuncts 
in the prevention of influenza, and effective when used early 
in the course of illness for treatment. Four influenza antiviral 
agents are licensed in the United States: amantadine, riman-
tadine, zanamivir, and oseltamivir.
During the 2007–08 influenza season, influenza A (H1N1) 
viruses with a mutation that confers resistance to oseltamivir 
became more common in the United States and other countries 
(450–452). As of July 2009, in the United States, approxi-
mately 99% of human influenza A (H1N1) viruses tested, and 
none of the influenza A (H3N2) or influenza B viruses tested 
have been resistant to oseltamivir. As of July 2, 2009, with few 
exceptions, novel influenza A (H1N1) viruses that began cir-
culating in April 2009 remained sensitive to oseltamivir (453). 
Oseltamivir resistance among circulating seasonal influenza A 
(H1N1) virus strains presents challenges for the selection of 
antiviral medications for treatment and chemoprophylaxis of 
influenza, and provides additional reasons for clinicians to test 
patients for influenza virus infection and to consult surveillance 
data when evaluating persons with acute respiratory illnesses 
during influenza season. CDC has published interim guide-
lines to provide options for treatment or chemoprophylaxis of 
influenza in the United States if oseltamivir-resistant seasonal 
influenza A (H1N1) viruses are circulating widely in a com-
munity or if the prevalence of oseltamivir-resistant influenza 
A (H1N1) viruses is uncertain (8). Updated guidance on 
antiviral use will be available from ACIP before the start of the 
2009–10 influenza season. This guidance will include a sum-
mary of antiviral resistance data from the 2008–09 influenza 
season, and will be published separately from the vaccination 
recommendations. Until the ACIP recommendations for use 
of antivirals against influenza are published, CDC’s previously 
published recommendations for use of influenza antiviral 
medications should be consulted for guidance on antiviral 
use (8). New guidance on clinical management of influenza, 
including use of antivirals, also is available from the Infectious 
Diseases Society of America (454).
Sources of Information Regarding 
Influenza and its Surveillance
Information regarding influenza surveillance, prevention, 
detection, and control is available at http://www.cdc.gov/flu. 
During October–May, surveillance information is updated 
weekly. In addition, periodic updates regarding influenza are 
published in MMWR (http://www.cdc.gov/mmwr). Additional 
information regarding influenza vaccine can be obtained by 
calling 1-800-CDC-INFO (1-800-232-4636). State and local 
health departments should be consulted about availability of 
influenza vaccine, access to vaccination programs, information 
related to state or local influenza activity, reporting of influenza 
outbreaks and influenza-related pediatric deaths, and advice 
concerning outbreak control.
Vaccine Adverse Event Reporting 
System (VAERS)
Adverse events after influenza vaccination should be reported 
promptly to VAERS at http://vaers.hhs.gov, even if the reporter 
is unsure whether vaccine caused the event. Clinically signifi-
cant adverse events that follow vaccination should be reported 
to VAERS at http://www.vaers.hhs.gov. Reports may be filed 
securely online or by telephone at 1-800-822-7967 to request 
reporting forms or other assistance.
national Vaccine Injury 
Compensation Program
The National Vaccine Injury Compensation Program 
(VICP), established by the National Childhood Vaccine Injury 
Act of 1986, as amended, provides a mechanism through which 
compensation can be paid on behalf of a person determined 
to have been injured or to have died as a result of receiving a 
vaccine covered by VICP. The Vaccine Injury Table lists the 
vaccines covered by VICP and the injuries and conditions 
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(including death) for which compensation might be paid. If 
the injury or condition is not on the Table, or does not occur 
within the specified time period on the Table, persons must 
prove that the vaccine caused the injury or condition.
For a person to be eligible for compensation, the general 
filing deadlines for injuries require claims to be filed within 3 
years after the first symptom of the vaccine injury; for a death, 
claims must be filed within 2 years of the vaccine-related death 
and not more than 4 years after the start of the first symptom 
of the vaccine-related injury from which the death occurred. 
When a new vaccine is covered by VICP or when a new injury/
condition is added to the Table, claims that do not meet the 
general filing deadlines must be filed within 2 years from the 
date the vaccine or injury/condition is added to the Table 
for injuries or deaths that occurred up to 8 years before the 
Table change. Persons of all ages who receive a VICP-covered 
vaccine might be eligible to file a claim. Both the intranasal 
(LAIV) and injectable (TIV) trivalent influenza vaccines are 
covered under VICP. Additional information about VICP is 
available at http//www.hrsa.gov/vaccinecompensation or by 
calling 1-800-338-2382.
Additional Information Regarding 
Influenza Virus Infection Control 
Among Specific Populations
Each year, ACIP provides general, annually updated infor-
mation regarding control and prevention of influenza. Other 
reports related to controlling and preventing influenza among 
specific populations (e.g., immunocompromised persons, HCP, 
hospital patients, pregnant women, children, and travelers) 
also are available in the following publications:
CDC. General recommendations on immunization:  •
recommendations of the Advisory Committee on 
Immunization Practices (ACIP) and the American 
Academy of Family Physicians (AAFP). MMWR 
2006;55(No. RR-15).
CDC. Influenza vaccination of health-care person- •
nel: recommendations of the Healthcare Infection 
Control Practices Advisory Committee (HICPAC) and 
the Advisory Committee on Immunization Practices 
(ACIP). MMWR 2006;55(No. RR-2).
CDC. Recommended immunization schedules for per- •
sons aged 0–18 years—United States, 2009. MMWR 
2009;57:Q1–4.
CDC. Recommended adult immunization schedule— •
United States, 2009. MMWR 2009;57:Q1–4.
CDC. Guidelines for preventing health-care–associated  •
pneumonia, 2003: recommendations of CDC and 
the Healthcare Infection Control Practices Advisory 
Committee. MMWR 2003;53(No. RR-3).
CDC. Respiratory hygiene/cough etiquette in health- •
care settings. Atlanta, GA: US Department of Health 
and Human Services, CDC; 2003. Available at http://
www.cdc.gov/flu/professionals/infectioncontrol/resphy-
giene.htm.
CDC. Prevention and control of vaccine-preventable  •
diseases in long-term–care facilities. Atlanta, GA: US 
Department of Health and Human Services, CDC; 
2006. Available at http://www.cdc.gov/flu/professionals/
infection control/longtermcare.htm.
CDC. Vaccine safety. Atlanta, GA: US Department of  •
Health and Human Services, CDC; 2009. Available at 
http://www.cdc.gov/vaccinesafety/index.htm.
American College of Obstetricians and Gynecologists.  •
Influenza vaccination and treatment during pregnancy. 
ACOG committee opinion no. 305. Obstet Gynecol 
2004;104:1125–6.
American Academy of Pediatrics. 2009 red book: report of  •
the Committee on Infectious Diseases. 29th ed. Elk Grove 
Village, IL: American Academy of Pediatrics; 2009.
Bodnar UR, Maloney SA, Fielding KL, et al.  •
Preliminary guidelines for the prevention and con-
trol of ILI among passengers and crew members on 
cruise ships. Atlanta, GA: US Department of Health 
and Human Services, CDC; 1999. Available at http://
wwwn.cdc.gov/travel/files/pre-guidelines-flu-cruise-
ships1999.ashx.
CDC. Infection control guidance for the prevention  •
and control of influenza in acute-care facilities. Atlanta, 
GA: US Department of Health and Human Services, 
CDC; 2007. Available at http://www.cdc.gov/flu/pro-
fessionals/infectioncontrol/health-carefacilities.htm.
Food and Drug Administration. FDA pandemic  •
influenza preparedness strategic plan. Washington, 
DC: Food and Drug Administration; 2007. Available 
at http://www.fda.gov/oc/op/pandemic/strategic-
plan03_07.html.
World Health Organization. Recommendations for  •
influenza vaccines. Geneva, Switzerland: World Health 
Organization; 2007. Available at http://www.who.int/
csr/disease/influenza/vaccinerecommendations/en/
index.html.
American Heart Association and American College  •
of Cardiology. Influenza vaccination as secondary 
prevention for cardiovascular disease. Circulation 
2006;114:1549–53. Available at http://circ.ahajournals.
org/cgi/content/full/114/14/1549. 
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